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Abstract 
 
Purpose: Despite the improvements achieved in the current therapy regimens, the 
development of prophylactic, safe and highly immunogenic vaccines to control and 
eradicate the Human Immunodeficiency Virus (HIV) remains one of the most exigent 
and challenging tasks. To prevent HIV infection, highly specialized antigen presenting 
cells, as dendritic cells (DCs), have to elicit effective humoral and cellular immune 
responses. In fact, the induction of both virus-specific neutralizing antibodies (IgG and 
IgA), at the site of viral entry, and cytotoxic T lymphocyte along with a Th1 response 
seem to be crucial to impair the dissemination of the virus. As a promising strategy for 
HIV delivery systems, polymeric nanoparticles (NPs) can protect HIV-1 antigens from 
unfavorable conditions after administration, in addition to acting as adjuvants by 
enhancing the antigen uptake by DCs. T20 and T1249 antigenic peptides are HIV-1 
fusion inhibitors derived from the gp41 helical region adjacent to the C-terminal 
sequence that have never been associated to a particulate delivery system. This project 
aims to design a HIV-1 vaccine throught the entrappement of HIV-1 antigenic peptides 
(T20 and T1249) into polymeric NPs.       
  Materials and Methods: Polymeric NPs were prepared by the double emulsion 
solvent evaporation method and characterized. Polyvinyl alcohol, block co-polymer 
Pluronic
®
 F127 and glycol chitosan were included in vaccine formulation to promote 
their potential adjuvant effect and/or improve NP stability. Model antigen ovalbumin 
and HIV-1 gp41 peptides, T20 and T1249, were entrapped or co-entrapped into NPs. 
Characterization of NPs was performed in terms of size, zeta potential and surface 
morphology by Dynamic Light Scattering, Laser Doppler Electrophoresis and Atomic 
Force Microscopy, respectively. Entrapment efficiency (EE, % (w/w)) and loading 
capacity (LC, µg/mg) of the entrapped agents were quantified by MicroBCA
®
, High 
Performance Liquid Chromatography and fluorescence. DCs were used to evaluate the 
in vitro cytotoxicity of NPs by the AlamarBlue
®
 assay and the cellular uptake and 
intracellular trafficking of rhodamine-labeled NPs by confocal microscopy. The peptide 
integrity was also assessed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis. 
Results: NPs presented mean diameters in the range of 170-180 nm, with a 
narrow size distribution (PdI < 0.15), surface charge close to neutrality and spherical 
shape. These antigen delivery systems presented high EE and LC, and no cytotoxic 
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effect on DCs, in the range of tested concentrations (0.125-1 mg/mL), after 24, 48 and 
72 h of incubation. According to NP physicochemical characteristics, PLGA-PEG_GCs 
formulation was selected for further studies. Peptide structure was maintained intact, not 
being affected by the double emulsion procedure. Confocal microscopy confirmed the 
internalization of NPs, demonstrating their endosomal localization and a tendency to 
accumulate close to the endoplasmic reticulum.     
Conclusions: The results herein described show that stable and reproducible 
PLGA-PEG_GCs NPs produced using a modified double emulsion solvent evaporation 
method constitute a promising platform for the successful delivery of HIV antigens to 
DCs, in order to develop a HIV-1 vaccine. 
 
Keywords 
 
HIV-1 vaccine, PLGA-PEG nanoparticles, HIV-1 gp41 peptides, targeted delivery 
systems, dendritic cells, intracellular trafficking     
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Resumo 
 
Objetivo: Apesar dos avanços alcançados nas terapêuticas atuais, o 
desenvolvimento de vacinas profiláticas, seguras e altamente imunogénicas para 
controlar e erradicar o vírus da imunodeficiência humana (HIV) continua a ser uma das 
tarefas mais exigentes e desafiantes. Para prevenir a infeção por HIV, as células 
apresentadoras de antigénio (APCs) altamente especializadas, têm de induzir respostas 
imunitárias humorais e celulares eficazes. Mais especificamente, a indução de 
anticorpos neutralizantes específicos contra o vírus (nomadamente as imunoglobulinas 
(Ig)G, IgA e IgE) secretados pelos linfócitos B, especialmente no local de entrada do 
vírus (resposta tipo Th2), e a estimulação de linfócitos T citotóxicos juntamente com 
uma resposta do tipo Th1 parecem ser cruciais para travar a disseminação deste vírus. 
Deste modo, a persistência da infeção por HIV parece estar intimamente associada à 
inadequada estimulação de uma resposta imunológica eficaz e específica capaz de 
destruir o vírus. Esta resposta é bastante complexa, não existindo uma correlação directa 
entre a infeção por este agente e eventuais mecanismos de proteção ou controlo da 
disseminação da doença.  
O HIV liga-se ao receptor CD4 via glicoproteína gp120 do invólucro viral, a qual 
sofre uma alteração conformacional, facilitando a sua ligação a um dos dois co-
recetores de referência, CCR5 ou CXCR4. A interação da gp120 com o recetor CD4 e 
os co-recetores é vital para que o vírus se ligue à célula. Contudo, para finalizar o 
processo de infeção vírus-célula, a glicoproteína gp41 do invólucro viral terá 
posteriormente de interagir com um recetor de fusão na célula. Após a fusão, o conteúdo 
viral é libertado para o interior da célula com a subsequente transcrição do RNA viral 
em DNA, que será transportado até ao núcleo e integrado no genoma celular, sendo 
posteriormente traduzido em proteínas. Estas proteínas virais, juntamente com o RNA 
viral, são transportados para a superfície celular iniciando a formação de novos viriões 
maduros. Os linfócitos T e B, os macrófagos e as células dendríticas (DCs) podem 
expressar os co-recetores CCR5 ou CXCR4, estando portanto suscetíveis à infeção por 
HIV. No entanto, apenas as DCs podem ligar-se à glicoproteína gp120 sem que haja 
fusão membranar. 
As DCs são atualmente reconhecidas como entidades fundamentais para a 
estimulação de uma resposta imunológica robusta e específica contra o HIV, a qual se 
deve à sua capacidade de migração para os órgãos linfáticos, zonas ricas em linfócitos 
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T, onde apresentarão os antigénios fagocitados e consequentemente levarão à 
estimulação dos linfócitos T CD4
+
 e CD8
+
, promovendo um eficiente e prolongado 
controlo da replicação do vírus no hospedeiro. No entanto, o papel destas APCs na 
imunologia do HIV está longe de ser um tema consensual. Estas células podem 
capturar, processar e apresentar o HIV desencadeando uma resposta eficaz e específica. 
Contudo, uma vez infetadas, as DCs podem infetar os linfócitos T, promovendo a 
disseminação do vírus e a progressão da doença. A fase crónica e assintomática da 
doença é caracterizada por um decréscimo da carga viral, persistindo o vírus latente em 
tecidos extravasculares, nódulos linfáticos, DCs e nos linfócitos T CD4
+
. Embora seja 
reconhecido o papel dos linfócitos T no controlo da infeção crónica por HIV-1, a 
imunidade especificamente induzida contra este microrganismo decresce após períodos 
prolongados da supressão do vírus, não conseguindo controlar a replicação do vírus e 
consequentemente originando a progressão da doença. Apesar destes doentes serem 
tratados com medicamentos antiretrovirais, reconhecidos como a melhor opção 
terapêutica atualmente disponível, estes tratamentos são dispendiosos, apresentam 
efeitos secundários significativos inerentes à sua toxicidade, dificultando a adesão à 
terapêutica por parte do doente por longos períodos. Mesmo na presença de 
medicamentos antiretrovirais, o vírus permanece latente no organismo em níveis não 
detetáveis, nomeadamente em linfócitos T CD4
+
 memória. Estes estão inativos, 
constituindo reservatórios que protegem o vírus da resposta imunológica e da 
terapêutica antiretroviral, tornando praticamente impossível a eliminação total do vírus 
com as abordagens terapêuticas actualmente disponíveis.  
O desenvolvimento de vacinas preventivas e de abordagens imunoterapêuticas 
contra a infeção por HIV tem sido bastante dificultado pela complexidade dos 
mecanismos imunológicos associados. De fato, a mutação do vírus, a capacidade deste 
ultrapassar a resposta imunológica humoral, bem como a manipulação das APCs 
evitando a maturação destas e portanto a eficaz apresentação dos antigénio aos 
linfócitos T, têm contribuído para a falta de eficácia obtida por inúmeros candidatos. 
Deste modo, torna-se desejável o desenvolvimento de novas estratégias capazes de 
modelar a resposta imunológica contra a infeção por HIV. As nanopartículas (NPs) 
poliméricas constituem sistemas promissores para o transporte de antigénios HIV-1. De 
fato, estes nanosistemas protegem os antigénios de HIV-1 das condições desfavoráveis 
após a sua administração e podem atuar como adjuvantes, aumentando o 
reconhecimento e a internalização de antigénios pelas DCs. Assim, este projeto único e 
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inovador tem como objetivo criar uma vacina contra o HIV-1 através da encapsulação 
dos péptidos antigénicos inibidores de fusão do HIV-1, derivados da sequência da  
região helicoidal adjacente ao C-terminal da gp41, T20 e T1249 em NPs poliméricas. É 
importante referir que estes péptidos de HIV-1 nunca foram associados a partículas 
poliméricas.  
Materiais e Métodos: As NPs poliméricas foram preparadas utilizando o método 
de dupla emulsão com a evaporação do solvente. O álcool polivinílico, o co-polímero 
Pluronic
®
 F127 e o glicol quitosano foram incluídos na formulação da vacina para 
promover o seu potencial efeito adjuvante e/ou aumentar a estabilidade das NPs. O 
antigénio modelo ovalbumina e os péptidos de HIV-1 gp41, T20 e T1249, foram 
incorporados ou co-incorporados nas NPs. A caracterização da NPs foi realizada tendo 
em conta o tamanho, a carga e morfologia da sua superfície por Dispersão Dinâmica de 
Luz, Dispersão Electroforética da Luz e Microscopia de Força Atómica, respetivamente. 
A eficiência de incorporação (EE, % (w/w)) e capacidade de carga (LC, µg/mg) dos 
agentes incorporados foram quantificados por MicroBCA
®
, Cromatografia Líquida de 
Alta Eficiência e fluorescência. As DCs foram usadas para avaliar a citotoxicidade in 
vitro das NPs através do ensaio AlamarBlue
®
 e a captura e tráfego intracelular das NPs 
marcadas com rodamina foram estudados por microscopia confocal. A integridade da 
estrutura dos péptidos foi ainda confirmada por electroforese em gel de poliacrilamida 
em condições desnaturantes, utilizando o dodecil sulfato de sódio. 
Resultados: As NPs apresentaram diâmetros médios compreendidos entre 170-
180 nm, com uma distribuição de tamanhos restrita (PdI < 0,15), carga superficial 
próxima da neutralidade e forma esférica. Estes sistemas de transporte de antigénios 
apresentaram elevados EE e LC, e nenhum efeito citotóxico em DCs, na gama de 
concentrações testadas (0,125-1 mg/mL), após 24, 48 e 72 h de incubação. Tendo em 
consideração os resultados previamente descritos, nomeadamente as características 
físico-químicas das NPs, a formulação PLGA-PEG_GCs foi selecionada para os 
restantes estudos. A estrutura dos péptidos foi mantida intacta, não sendo afetada pelo 
processo de dupla emulsão. A microscopia confocal confirmou a internalização das 
NPs, demonstrando a sua localização endosomal e uma tendência para se acumularem 
perto do retículo endoplasmático. 
Conclusões: Os resultados aqui descritos mostram que NPs estáveis e 
reprodutíveis foram produzidas utilizando um método de dupla emulsão com 
evaporação de solvente modificado. Importa no entanto realçar que as NPs PLGA-
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PEG_GCs constituem uma plataforma promissora para o transporte e eficaz 
apresentação de antigénios de HIV, tendo em vista o desenvolvimento de uma vacina 
eficaz contra a infeção por HIV-1. 
 
Palavras-chave 
 
Vacina contra a infeção por HIV-1, nanopartículas PLGA-PEG, péptidos de HIV-1 
gp41, sistemas de transporte, células dendríticas, tráfego intracelular     
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1. State of art 
 
1.1. Incidence and mortality 
 
The Human Immunodeficiency Virus (HIV), the causative agent of Acquired 
Immune Deficiency Syndrome (AIDS) was identified in the early 1980s and became an 
increasing global health, social, and economical concern (1). HIV/AIDS has high 
prevalence rates in developing nations, such as sub-Saharan African countries and other 
important regions including the Caribbean, Latin America, and South and Southeast 
Asia, with important socioeconomic, family, and public health burdens (2). 
In 2007, it was estimated that 33 million of people were infected by HIV and 25 
million have died since the first reported cases. Moreover, two million of new infections 
as well as deaths per year are annually reported. Despite the increased number of new 
infectious per year, Joint United Nations Program on AIDS (UNAIDS) reported a slight 
decrease in HIV pandemic since the beginning of the 21st century (2.7 million in 2007 
vs. 3.0 million in 2001), justified by the expanding access to antiretroviral drugs that 
increased lifespan and the quality life of HIV infected people (3).  
 
1.2. Biology of HIV 
 
HIV belongs to the genus Lentivirus and the family of Retroviridae (4). The virus 
is a spherical nanostructure (around 100-150 nm) composed by an outer viral envelope 
and an inner nucleocapsid enclosing the genetic material in the form of two copies of 
single stranded ribonucleic acid (RNA). The RNA genome (9.5 kB) contains nine genes 
that code for structural (Gag, Pol and Env), regulatory (Tat and Rev) and accessory 
(Nef, Vif, Vpr and Vpu) proteins (5). Gag protein is cleaved into matrix (p17), capsid 
and nucleocapsid (p24) proteins. Env is a homotrimeric type I integral membrane 
protein cleaved into glycoprotein 160 (gp160) that forms two noncovalently attached 
envelope glycoproteins embedded in the lipid bilayer of outer viral membrane, gp120 
surface protein and gp41 transmembrane protein, responsible for the virus/cell fusion 
subsequent to the recognition of CD4 receptor and CCR5 or CXCR4 coreceptors 
present on host cell membrane (6). The Pol protein encodes essential viral enzymes 
such as reverse transcriptase, integrase and protease that are enclosed within a cage of 
capsid and matrix (4). Regarding accessory proteins, Vif can infect otherwise non-
permissive cell types inducing productive infections and allowing the increase of viral 
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infectivity; Vpr transport the viral genome to the nucleus in the viral life cycle; and Vpu 
and Nef degrade cellular CD4 receptor and increase virus budding/spreading (7). 
Summarizing, HIV retrovirus contains the RNA genome into the nucleocapsid, which is 
converted to deoxyribonucleic acid (DNA) by reverse transcriptase and inserted into 
host cell genome, causing an extended and lethal disease.  
Two distinct types of HIV (HIV-1 and HIV-2) were identified as causative agents 
for HIV infection and disease in humans (8). Apart from other differences, such as their 
geographical origin and the organization of their genome, HIV-1 is the most prevalent 
and efficiently transmitted, associated with a faster progression to immunodeficiency 
(9). HIV-1 is divided into three groups: the prevalent M, N and O. The M group is 
responsible for most of the epidemic and contains eleven subtypes termed A-K, where 
B causes the majority of infections in America, Europe, Asia and Australia, whereas 
subtypes A, C, D and E are widely founded in Africa (10). HIV-2 mostly prevalent in 
West Africa, India, Portugal and Portuguese African colonies is diversified into eight 
virus groups termed A–H, being group A the most prevalent (11). 
 
1.3. HIV infection process 
 
HIV infects preferably cell types that express cell-surface protein CD4 such as 
macrophages, lymphocyte T-cells and dendritic cells (DCs) (12). HIV entry into the 
target cell can be divided into three steps: attachment, coreceptor interaction and fusion. 
Attachment of HIV-1 to host cell membrane is not an easy task and is mediated by the 
Env protein (13). Env is synthesized as gp160, a complex of noncovalently associated 
glycoproteins that is cleaved during the transport to the cell surface into two vital 
glycoproteins for viral binding to human cells, gp120 and gp41 (120 and 41 kDa, 
respectively). At the beginning of HIV entry process, the viral envelope gp120 interact 
with the host cell-surface receptor CD4. Consequently, conformational changes and 
structural rearrangements are induced in gp120 exposing the coreceptor-binding site and 
allowing its binding to a chemokine coreceptor (CXCR4 or CCR5) on the host cell 
surface (14). Together, CD4 and coreceptor binding trigger additional fusogenic 
conformational changes in gp41 that cause its release and insertion into the host cell 
membrane, completing the fusion process between virus and target cell (15, 16). 
Specifically, HIV-1 gp120 contains an inner core constituted by five conserved protein 
domains (C1-C5) that interact noncovalently with gp41 transmembrane protein, forming 
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a i) trimeric envelope spikes; ii) an outer structure composed by five variable protein 
domains (V1-V5); and iii) numerous N-linked glycosylation sites that forms the most 
part of the spike-exposed surface. This surface protein mediates virus binding to cellular 
receptors. Particularly, the interaction between gp120 and CD4 receptor induces a 
conformational change leading to the formation of a third domain or bridging sheet, 
responsible for the interaction of inner and outer domains with viral coreceptors (14). 
HIV-1 gp41 is composed of three domains (an extracellular termed ectodomain, a 
transmembrane and an intracellular named endodomain) that constitute the 
transmembrane subunit of Env, embedded in the viral membrane by their 
transmembrane domains. Through the ectodomains, gp41 and the Env surface subunits 
constituted by gp120 molecules remains noncovalently associated. Immediately after 
gp120-coreceptor binding, the gp120-gp41 complex is dissociated and the unstable 
gp41 structure is released, exposing a fusion domain. Subsequently, the fusion peptide 
present on gp41 ectodomain is inserted into the lipid cell membrane, eliciting the virus-
cell anchoring. Following the insertion, two heptad-repeated helical regions (HR) 
adjacent to the N- and C-terminal (NHR and CHR, respectively) of the ectodomain are 
energetically reorganized under conformational changes, creating a thermostable trimer 
of heterodimers termed six-helix bundle (6HB) structure. This 6HB consists of three 
NHR domains in the inner core and three CHR domains packed on the outside and 
associated with NHR domains in an antiparallel manner, representing the fusion-active 
core of gp41 (17). As a result, the fusion peptide and transmembrane domain of gp41, 
along with their associated membranes, are brought into close proximity producing a 
juxtaposition of viral and host cell membranes and their complete fusion (18, 19). 
Following the fusion process, the capsid core is disrupted and the viral content 
containing RNA, reverse transcriptase and integrase, is released inside the host cell 
cytoplasm. After the successful entry of the content, the viral RNA template is degraded 
and reverse transcribed into its complementary DNA strand by the viral enzyme reverse 
transcriptase associated with other viral proteins, producing a double-stranded viral 
DNA. The newly synthesized viral DNA is then transported to the host cell nucleus 
where is processed and inserted into the host cell genome by viral enzyme integrase 
(20). Once transferred viral DNA, the target cell is permanently infected. Without cell 
stimulation, the HIV can persist as a provirus in a latent state for several years (21). 
However, host cell activation will elicit the transcription of proviral DNA into viral 
RNA by RNA polymerase, the viral RNA transport outside the nucleus and its 
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translation into viral proteins by the ribosome. The newly produced viral proteins 
(capsid, envelope and auxiliary proteins) together with two copies of the viral genomic 
RNA are transported to the cell surface beginning the assembly of new virus particles 
(22). This assembly induces a curvature in plasma membrane allowing that non-
infectious and immature virions sprouting from host cell, with its consequent explosion. 
The immature virion is then reorganized into its mature form with the help of HIV 
protease that cleaves the Gag and Pol polyproteins into their structural proteins and 
functional enzymes (10). The HIV entry process described above is illustrated on Figure 
1.  
 
Figure 1 – HIV infection process. 
 
1.4. HIV transmission 
 
HIV-1 is transmitted through the horizontal route, that includes hetero- or 
homosexual contact (vaginal or anal sexual intercourse), or contaminated blood contact 
(blood transfusions, drug addiction: sharing of contaminated needles among injected 
drug users, accidents); or vertical route from mother to child during pregnancy, at 
childbirth or during breastfeeding (23). Overall, the efficiency of HIV-1 transmission is 
dependent on the concentration of virus in body fluids (blood, semen, vaginal secretions 
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and breast milk contain higher virus load) and the immunological and cellular host 
vulnerability (24). 
Regarding the sexual contact, HIV can penetrate in vaginal and cervical mucosa 
either as free virions or cell associated, being macrophages the primary transmission 
carriers (25). In the genital mucosa, the presence of several immune cells mainly DCs, 
macrophages, T and B lymphocytes that express either CXCR4 or CCR5 coreceptors, 
enhance the spread of the virus (26). In addition, the unique capacity of DCs to binding 
HIV gp120 without the membrane fusion process due to the presence of a dendritic cell-
specific HIV-1 binding protein, DC-SIGN (dendritic cell specific intercellular adhesion 
molecule-grabbing non-integrin), facilitates the viral transport to secondary lymphoid 
organs increasing the infectivity of HIV in T cells (27). Moreover, epidermal immature 
DCs, named Langerhans cells (LCs), are abundant in the cervico vaginal epithelium and 
can extend the initial HIV replication (local amplification) through the uptake of HIV 
antigens, mediating its transmission across intact genital epithelium and presenting them 
to specific T cells in the surrounding tissues (28). The capacity of all DCs, including 
infected/HIV-bearing LCs, to carry virions across the epithelium due to their ability to  
migrate to T cell-rich lymph nodes, has highlighted their crucial role in vaginal HIV 
transmission (29). 
Rectal transmission is also a straightforward route for viral infection enhanced by 
the presence of a single columnar epithelial lining in rectum and terminal colon. Mainly, 
M cells abundant in these tissues can present antigens to sub-epithelial lymphocytes and 
macrophages ensuring its constant lumen sampling (30). 
It has been known that HIV-1 replicates more promptly in target cells co-cultured 
with infected cells, unlike cell-free virus inoculation (31). HIV-1 cell-to-cell 
transmission requires transient adhesive junctions between infected and target cells (32). 
Two types can be differentiated by the infection status of the donor cell. Virological 
synapse (VS), also known as cis-infection, is formed by HIV-infected cells. The binding 
of Env expressed by the infected donor cell to CD4 receptor on the target cell is a 
characteristic of transmission via VS. VS assembly and target cell infection is also co-
receptor and fusion-dependent (33). In contrast, infectious synapse (IS) is formed by 
uninfected cells that have captured free HIV-1. This process also known as trans-
infection is mediated by a variety of DC receptors (DC-SIGN, sialic acid-binding 
immunoglobulin-type lectin (Siglec)-1 and heparin sulphate proteoglycans) used to 
capture HIV-1 virions and to maintain them in an infectious state adsorbed within 
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complex surface-connected plasma membrane invaginations. The surface-bound virus 
will be released after the contact between DCs and uninfected target cell, such as a 
CD4
+
 T helper (Th) lymphocyte, interacting with receptors on the target cell (34). In 
addition, the transfer either via VS (infected immature DCs) or IS (uninfected mature 
DCs) can be directed by DC maturation cycle, where DC phenotype varies from an 
immature state with higher phagocytic ability in the mucosal tissues to a mature state 
with higher ability to present antigen in lymph nodes. It has also been reported that 
mature DCs are resistant to HIV-1 infection but also much more efficient at HIV-1 
trans-infection, whilst immature DCs are capable of limited HIV-1 replication (35). 
 
1.5. HIV pathogenesis and immune response 
 
Clinically, HIV-1 infected patients may undergo three stages: acute phase, chronic 
phase (first asymptomatic and later non-AIDS defining symptoms) and terminal or 
illness phase, defined by AIDS.    
During the following days post initial infection, the virus readily infects CD4
+
 Th 
cells to produce new virions (up to 10
10
 new virus particles/day) being locally 
amplified, at the mucosal site. Accordingly, virus spreads as free or infected cell-
associated form, via regional lymph nodes from the local entry to lymphoid organs, 
principally the gut-associated lymphoid tissues (GALT), spleen and bone marrow, being 
accompanied by a burst in viral replication (acute infection) (36). Until the first six 
weeks, a high viral load expressed as several million of viral genomic RNA copies/mL 
plasma and the fast depletion of CD4
+ 
 Th and CD8
+
 T cytotoxic (Tc) cells are particularly observed in the peripheral 
blood and gastrointestinal tract, where there is a massive viral production (37). During 
this acute phase exists an increased risk for sexual HIV transmission consequence of 
high blood and genital viral load (38). Moreover, a proportion of the newly infected 
patients have experienced the clinical “acute phase syndrome” described by fever, 
fatigue, sore throat, skin rash, enlarged lymph nodes, diarrhea, nausea and general 
malaise symptoms. Within six months post infection, the immune system reacts with 
specific cellular responses and HIV-1 specific antibodies, which recovers immediately 
and gradually CD4
+
 Th and CD8
+
 Tc cell levels, respectively. Never completely 
depleted, viral load is reduced attaining a steady state viremia (viral setpoint) defined by 
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the equilibrium between viral replication (fitness) and viral suppression by the intense 
immune response (latent phase) (39). 
During the chronic phase, characterized initially by the absence or presence of 
residual clinical symptoms, in addition to the high viral mutation rate and virus 
persistence in several reservoir sites, is observed an exhaustion of the immune system 
accompanied by T-cell depletion. The last, especially the continuous decrease of CD4
+
 
Th cells is a result of the i) limited regeneration capacity of the immune system 
(including thymic atrophy in adults), ii) direct morphologic alterations of infected cells 
(cytopathic effects), iii) loss of CD8
+
 Tc cell response efficacy, iv) apoptosis of 
uninfected CD4
+
 Th and CD8
+
 Tc lymphocytes and v) lymphoid organs degeneration. 
Moreover, the depletion of T cells, especially the massive loss of CD4
+
 Th cells in 
gastrointestinal tract, may affect the protective barrier of the intestinal mucosa, allowing 
bacteria and bacterial toxins such as lipopolysaccharide (LPS, a cell-wall component of 
Gram-negative bacteria) and possibly gastrointestinal viruses to cross into blood 
circulation, inducing a pathological over-activation of the immune system (40). 
Furthermore, T regulatory (Treg) lymphocytes, a subset of T cells with suppressor 
activity capable of blocking the activation (proliferation and cytokine production) of T 
cells (41), have appeared increased in the GALT during HIV infection. Treg cells were 
reported as protectors from productive infection and pathogenic disease (42); but, on the 
other hand, Treg cells were associated with the establishment of HIV infection in 
humanized mice (43). Therefore, whether this accumulation prevents disease 
progression by inhibition of immune activation or increases opportunistic infections 
probability in gastrointestinal tract remains unclear. Consequently, immune response 
influenced by Treg cells against HIV infection may be destructive, resulting in diseases 
such as lymphoid interstitial pneumonitis and autoimmunity (e.g. immune 
thrombocytopenic purpura), or protective. (44) A possible explanation for such 
diverging results is arguably the heterogeneity of this population, not exclusive to HIV-
infection. Treg cells are mostly characterized based in the expression of surface markers 
(CD4
+
, CD25
+
, CD127
-
) and the transcription factor FoxP3. However, the phenotypic 
characterization of HIV, wherein different CD4 subsets become infected with different 
kinetics, can affect the expression of Treg surface markers, CD4
+
 Th cell plasticity and 
FoxP3 stability (45).   
Finally, the loss of immune surveillance characterized by decreased CD4
+
 Th cell 
counts and rising viral load, causing the appearance of opportunistic infections normally 
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prevented by cell-mediated immunity (i.e. infections with mycobacteria, fungi, protozoa 
and viruses), leads to a symptomatic clinical stage, designated by AIDS, within about 
ten years after primary infection for the majority of rapid progressors (46). The 
progression of infection is also encouraged by the increase of HIV genetic diversity due 
to intense error-prone reverse transcription and evolutionary pressure to evade the 
immune system, generating viruses resistant to cellular and humoral immune responses. 
Nevertheless, a curious small number of individuals named long term survivors or non 
progressors remain without symptoms, with stable CD4
+
 Th cells number and low to 
intermediate viral loads, for more than ten years (47). The rapid progressors and long 
term non-progressors differ in the immune system ability to control virus infection. 
More curiously, in normal survey people it was discovered an apparently harmless 
mutation (the D32 mutation), which results in CD4
+
 Th cells not presenting CCR5, 
capable to confer a natural resistance to HIV infection (48). 
 
1.5.1. HIV reservoir sites 
 
Reservoir sites are cellular or anatomical locations able to protect the virus from 
biological elimination ensuring a persistent and undetected replication. Overall, cellular 
reservoirs are particularly composed by macrophages, lymph node DCs and memory 
CD4
+
 Th cells and allow the residence and surviving of HIV infection for long periods 
(49). Mainly, macrophages are important viral reservoirs outside the bloodstream able 
to transport HIV and infect the central nervous system (CNS), causing neurocognitive 
disorders, namely HIV-associated dementia. This cell population is also the key in 
maintaining the HIV replication cycle when CD4
+
 Th cells are largely depleted, at later 
stages of infection (50). Anatomical reservoir sites of HIV include mainly lymphoid 
organs (in particular the spleen, lymph nodes, and GALT) and CNS, but also testicles 
and female genital tract (51). As discussed above, lymphoid organs are directly implicit 
in the circulation and production of HIV-susceptible lymphocytes, being its destruction 
well correlated with progressive HIV disease.   
 
1.5.2. Humoral immune response against HIV 
 
In order to control viral transmission preventing infection of host cells, the 
adaptative immune system induces a humoral immune response mediated through the 
production of virus-specific antibodies by B lymphocytes (52). Post infection, 
extracellular viral proteins are taken up by antigen presenting cells (APCs), essentially 
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DCs, macrophages and B cells; and processed into small peptides that will be presented 
to CD4
+
 Th cells once complexed with major histocompatibility complex (MHC) class 
II molecules at cell surface. In particular, the activation of Th2 cells will stimulate naïve 
B cells through the production of cytokines, including interleukin (IL)-4, IL-5, IL-6, IL-
10 and transforming growth factor (TGF)-β. Therefore, specific epitopes or intact virus 
recognize the surface of immunoglobulin (Ig)M on naïve B cells inducing their 
differentiation into both antibodies-producing plasma cells (IgG, IgA, IgE) and memory 
B cells. Within the antibodies produced a few weeks to several months after HIV-1 
infection against gp120, gp41, the nucleocapsid (p24) and the matrix (p17), mainly anti-
HIV Env antibodies predominantly target one of the three crucial regions for viral entry 
into CD4
+
 Th cells (gp120, gp41 or the binding sites for CD4 and CXCR4 or CCR5 co-
receptors), presenting a neutralizing capacity able to prevent virus attachment or inhibit 
the viral entry. Moreover, antibodies can attach and kill HIV infected cells via antibody 
dependent cellular cytotoxicity mediated by their Fc moiety and natural killer (NK) cells 
(53, 54). However, the virus easily mutates and escapes from immune pressure exerted 
by autologous neutralization, which uses a minority of anti-HIV Env antibodies (55). In 
addition, the ability to neutralize heterologous viruses using generated broadly 
neutralizing antibodies (bNAbs) is achieved by only 20% of infected individuals during 
the chronic infection, being insufficient to control or eliminate established HIV-1 
infection (56). As expected, long-term non-progressor individuals present a strong 
neutralizing antibody response.       
 
1.5.3. Cellular immune response against HIV 
 
When the viremia peak attain the maximum level within 1-2 weeks, specific 
cellular immune responses mediated by CD8
+
 Tc lymphocytes are triggered as other 
arm of the adaptative immune system to combat viral infection. MHC class I molecules 
at cell membrane display peptide fragments resulting from intracellular processing of 
viral proteins, by the proteasome, for recognition by CD8
+
 Tc lymphocytes. In this case, 
the engagement of T cell receptors with MHC-peptide complexes activates Th1 cells, 
producing IL-2, interferon (IFN)-γ and tumor necrosis factor (TNF)-α, which induce 
CD8
+
 Tc lymphocytes maturation and differentiation into memory or effector cells. 
CD4
+
 Th cells induced by APCs are a crucial help in an optimal CD8
+
 Tc cell response 
through the secretion of cytokines and the modulation of cellular functions. Specifically, 
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after massive depletion during acute phase, the remaining CD4
+
 Th cells need to 
produce at least IL-2 and IFN-γ to proliferate after antigen stimulation and provide help 
to CD8
+
 Tc lymphocytes (57). Polyfunctional CD8
+
 Tc cells producing IFN-γ, TNF-α, 
IL-2, macrophage inflammatory protein (MIP)-1β, perforines and granzymes display the 
capacity to exert different effector functions such as: i) directly eliminate HIV-infected 
cells; ii) induce apoptosis of infected cell through the interaction between the Fas ligand 
on CD8
+
 Tc cells and Fas receptor on infected T cells; and iii) suppress virus replication 
and block viral entry into CD4
+
 Th cells, controlling partially the viremia (58). To 
promote polyfunctional CD8
+
 Tc cells and initiate target cell lysis more rapidly, a strong 
avidity of T cell receptor for the epitope-MHC class I-complex is necessary (59). 
However, the introduction of escape mutations in specific CD8
+
 Tc cell epitopes (60), 
the Nef-mediated down-regulation of MHC class I, the rate of cytokine production and 
T-cell signaling, and the CD4
+
 Th cell function weakness (61) become responsible for 
virus escape from CD8
+
 Tc mediated cell response, resulting in a reduced control of the 
infection and an increased viral load.  
 
1.6. Antiretroviral therapy 
 
Despite the HIV ability to persist in cellular and anatomical reservoir sites (latent 
state), currently the best option to preserve the immune system after HIV infection, 
prolonging and maximizing viral suppression, is the antiretroviral therapy (ART) (62). 
The first antiretroviral drug, a nucleotide mimic that targets HIV-1 reverse transcriptase, 
was introduced in the mid-1980s (63). Over the years, more than 30 individual 
antiretroviral drugs to treat HIV infection were developed, being inserted into different 
classes such as reverse transcriptase inhibitors (RTI), protease inhibitors (PI), entry 
inhibitors (CCR5 antagonists and fusion inhibitors), and integrase inhibitors.  
Usually, antiretroviral treatment leads to increase levels of CD4
+
 Th cell, 
improving their function and immune competency (64). Additionally, the application of 
highly active antiretroviral therapy (HAART), that involves the use of agents from at 
least two distinct classes of antiretrovirals, can suppresses viremia and partially restores 
CD4
+
 Th cell number, improving the lifespan expectancy of patients infected with HIV-
1 (65). However, most of these antiretroviral drugs displays inadequate 
physicochemical properties (e.g. poor solubility, permeability and stability) which affect 
the optimal absorption, biodistribution and sustained antiretroviral effect. Furthermore, 
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these therapies presents several disadvantages such as the inherent toxicity caused by 
the lifelong treatment with important adverse effects (cardiovascular complications (66), 
renal and hepatic diseases, lipodystrophy and diabetes mellitus (67)), insufficient 
efficacy, drug resistance, drug interactions, poor bioavailability, increase in viral load 
post therapy cessation and high costs (~US$10 000 per patient per year), particularly for 
drugs recently approved (68). Predominantly, drug resistance has been reported for each 
antiretroviral drug currently used in HIV therapy, being the most common cause of 
antiretroviral treatment failure (69). As a result, it is necessary the continual 
development of new inhibitors that can be used against resistant strains of HIV-1 virus, 
as well as, new classes of drugs against unexploited targets. Also, cheaper and more 
widely available therapies to suppress and/or eliminate the viral reservoirs, even if the 
treatment is stopped or interrupted, are a clearly need. 
Taking into account the lifelong treatment exposure, costs, the risk of 
antiretroviral drugs and the incapacity to restore effective HIV-specific T cell responses, 
vaccination is a generally considered approach to tackle all these problems.         
 
1.7. HIV vaccine development 
 
The future control of the HIV-1 pandemic is based on the development of a safe, 
effective and inexpensive HIV vaccine for therapeutic and/or prophylactic use. HIV 
vaccine development is perhaps the most important and challenging goal remaining in 
HIV-AIDS research and its discovery will contribute to the solution of one of the major 
global health problem of our time. The RV144 trial (Thailand) recently reported the 
successful use of a prime-boost combination of two vaccines: a canarypox-HIV 
recombinant vector encoding Gag, Pro and gp120 followed by a recombinant gp120 
protein, which prevented HIV infection (31.2% efficacy) (70). In fact, a HIV vaccine 
development is a major research challenge due to the numerous infection-related 
hurdles including the virus latency, the high genetic variability, the potential cell-to-cell 
transmission and the down-regulating MHC class I in infected cells (71). Accordingly, a 
HIV vaccine must prevent the acquisition of infection, inducing a durable and robust 
protective immunity (prophylactic effect) and/or stimulate sufficiently potent immune 
responses that limits virus replication in infected persons in order to diminish disease 
progression and viral transmission (therapeutic effect) (72). To prevent or control HIV 
infection, the new vaccine have to induce the production of bNAbs, activate HIV-
12 
 
specific CD4
+
 and CD8
+
 T cells, polyfunctional T cell responses and induce long-term 
memory cells (73). 
In fact, prophylactic vaccines focus on limiting viral entry into host cells through 
the production of broadly reactive anti-HIV neutralizing antibodies (mainly IgG and 
IgA) that bind to free virus particles, crucially on mucosal tissues. Despite the extreme 
variability of HIV Env antigenic epitopes complicating the induction of bNAbs, HIV-
neutralizing IgA antibodies have been isolated in uninfected individuals frequently 
exposed to the virus (74). In addition, the passive transfer of human neutralizing 
antibodies in animal models can protect against viral challenge (75). However, an 
enormous quantity of antibodies is needed for the protection of viral transmission. The 
strategy is also based on high quality CD8
+
 Tc memory and effector cells to eliminate 
infected cells if cellular infection prevented by antibodies fails, stimulating 
polyfunctional and sustained CD4
+
 Th responses (76). Moreover, such vaccine should 
induce HIV specific CD8
+
 Tc cell to eliminate infected cells and CD4
+
 Th cells to help 
in the induction and maintenance of B and CD8
+
 Tc cell responses (77). 
Therapeutic vaccine have to enhance HIV-1 specific CD4
+
 Th and CD8
+
 Tc cell-
mediated immune responses in infected individuals to control virus replication and 
eliminate infected cells (78). 
 
1.7.1. Antigens, adjuvants and delivery systems 
 
Vaccine strategies use antigens to be recognized by the immune system promoting 
the induction of an adaptive immune response. Traditional HIV vaccines designed to 
mimic natural infection are mainly composed of live attenuated or inactivated virus, 
which often cause many undesired side effects for human use (79). Unsafety of these 
vaccines and advances in biotechnology encouraged the development of new vaccine 
strategies using part of the pathogen, such as recombinant or synthetic proteins or 
peptides, or nucleic acids such as plasmid DNA (pDNA) or messenger RNA (mRNA) 
encoding viral proteins. As compared to pDNA, mRNA is easier to engineer, effective 
in protein production not needing to cross the nuclear membrane (80), and eliminates 
the insertion of mutations on cell genome (81). Despite the greater safety of these 
antigens comparing with live attenuated or killed pathogens, they are typically 
insufficiently immunogenic to initiate adaptative immune responses when administered 
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alone; therefore, adjuvants or vaccine delivery systems are necessary to induce an 
adequate immunity (82). 
The development of long-lasting antigen-specific immune responses implies an 
adjuvant which stimulates the innate and adaptative immune system, more specifically 
by activating APCs. Therefore, an effective adjuvant will help the long-term efficacy of 
antigen vaccines (83). Furthermore, delivery systems are also required to insure an 
optimal, protector and modulator delivery of single or multiple vaccine antigens and/or 
adjuvants to APCs, in a targeted and prolonged manner (84). In fact, when administered 
alone, antigens tend to elicit a Th2-type immune response or even tolerance to the 
antigen, while when co-administered with adjuvants tend to induce Th1-type immune 
response. Aluminium-based adjuvants (generally referred to as alum) were the first 
vaccine adjuvants to be widely used worldwide, being the only ones approved by the 
Food and Drug Administration (FDA) for human use more than 60 years (85). Although 
alum adjuvants are generally well tolerated, they have important side effects and safety 
concerns such as the formation of granulomas after injection, increase of vascular 
permeability, toxic effects to macrophages, and if renal function is poor, their higher 
toxicity can be linked to neurodegenerative disorders, including Alzheimer’s disease 
(86, 87). Alum is not suitable for all antigens and is a weak adjuvant for producing 
antibodies and initiating cell-mediated immunity (88). Consequently, a great need exists 
for new, safe and potent immunostimulatory adjuvants and antigen delivery systems 
able to stimulate both Th1 and Th2-type immune responses. There are several other 
experimental adjuvants that have been shown to activate APCs more directly, including 
LPS and unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpG). 
However, the administration of high doses of these adjuvants seems to cause toxic 
effects. Particularly, repeated daily injections of CpG in mice for 14 days of treatment 
damaged lymphoid tissues and caused hepatic toxicity (89). Other types of adjuvants, 
including microemulsions (MF59 or Freund incomplete adjuvant) and saponins (QS-21) 
were approved for human use in Europe (90). However, adjuvant safety and efficacy on 
a wide scale have yet to be confirmed. Thus, improved adjuvants such as particulate 
systems have demonstrated both non-toxic and strongly immunogenic characteristics 
required for developing new vaccine technology. The latter also act as a delivery system 
carrying immunostimulatory molecules and promoting the presentation of vaccine 
antigens to the immune system. HIV vaccine delivery systems based on particulate 
adjuvants, such as liposomes, virosomes, immunostimulating complexes (ISCOMs), 
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emulsions and biocompatible polymeric nano- and microparticles have been widely 
investigated due to their safety profile, ability to protect and enhance immunogenicity of 
antigens, when delivered by diverse administration routes (e.g. intramuscular (IM), 
subcutaneous (SC), intradermal (ID), and intranasal (IN)) (91). 
 
1.7.1.1. Polymeric nanoparticles as HIV vaccine delivery system 
 
Biodegradable polymeric nanoparticles (NPs) or nanospheres are colloidal 
nanosystems composed of natural or synthetic macromolecular substances, having a 
size range between 10 and 1000 nm (92). Hydrophobic or hydrophilic HIV drugs, as 
well as biomolecule-like proteins, peptides, pDNA and small interfering RNA (siRNA) 
can be loaded into polymeric NPs through dissolution, encapsulation, adsorption or 
conjugation (93). These nano-scaled polymeric particles have shown a great potential to 
become the next generation vaccine delivery systems/adjuvants due to the protection of 
antigens from proteolytic degradation in vivo after systemic or mucosal immunization 
and the enhancement of antigen uptake by APCs in a targeted manner, facilitating the 
induction of potent immune responses comparing to soluble molecules (94). 
Furthermore, polymeric NPs facilitate co-delivery of other immunomodulators or 
adjuvants. Moreover, these nanocarriers are a sustainable source of retained antigens 
releasing them in a sustained manner for a long period to APCs (depot effect), avoiding 
the need for repeated administrations (95). In addition, formulation process and scaling-
up of polymeric NPs are much easier and less expensive than liposomal formulations, 
especially in terms of ability to manipulate several physicochemical properties (96). In 
summary, polymeric nanosystems present good toxicity profile, possibility of drug-
release modulation, high drug payloads, relative low cost, easiness to produce and 
possible scaling up. Using polymeric nanocarriers, the drug uptake is increased and cell 
toxicity is diminished, due to the slow-release properties of these systems. Particularly, 
synthetic polymers such as poly(lactic acid) (PLA), poly(γ-glutamic acid) (PG), 
poly(lactic-co-glycolic) acid (PLGA), poly(caprolactone) (PCL), poly(methyl 
methacrylates) (PMMA) and natural polymers like chitosan (Cs) are widely used for the 
formulation of nanoparticulate delivery systems for HIV vaccines. 
Liard et al. (2011) investigated the cellular and humoral immune responses in 
mice after injection of HIV-1 p24 antigen-coated PLA NPs by three different skin 
layers, transcutaneous (TC), ID and SC application. Regarding the cellular response, TC 
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and ID routes induced significant levels of p24-specific CD8
+
 effector T cells producing 
IL-2, TNF-α and IFN-γ cytokines, as well as p24-specific CD4+ Th cells. Higher levels 
of systemic p24-specific IgG1 and IgG2a antibodies were produced by ID and SC 
immunization (humoral immunity). As a primary line of protection, a higher number of 
vaginal mucosa CD8
+
 Tc cells was found after TC and ID skin immunizations. 
Significant levels of vaginal p24-specific IgA were generated choosing ID and TC skin 
routes for priming. Thus, systemic and mucosal cellular and humoral responses are 
influenced by the skin route of p24-coated PLA NPs vaccine administration (97). 
Caputo and colleagues (2009) developed anionic surfactant-free nanospheres as 
HIV-1 vaccine carriers composed of a PMMA polymeric-inner core with Tat antigen 
electrostatically linked onto hydrophilic anionic Eudragit L 100-55 outer surface. HIV-1 
vaccines administered by IM, SC or IN routes revealed efficient and long-lasting 
cellular (Tat-specific cytotoxic T lymphocytes) and humoral (IgG) immune responses in 
mice elicited by particulate systems as opposed to Tat alone or Tat delivered with alum 
adjuvant (98). 
Another example was shown by Himeno et al. (2010) evaluated immune 
responses and protective efficacy against an inoculation of simian and human 
immunodeficiency chimeric virus (SHIV) after rhesus macaques’ immunization with 
HIV gp120-carrying PG NPs. Despite PG NPs did not offer protection against SHIV in 
macaques, maintaining higher values of viral load, they induced stronger responses for 
both gp120-specific cellular and humoral immunity than gp120 in solution (99). 
Zhu et al. (2012) developed PLGA NPs encapsulating a CD4
+
 Th cell epitope 
fused with an HIV Env CD8
+
 Tc lymphocyte epitope and toll-like receptor (TLR) 
ligands (macrophage-activating lipopeptide (MALP)-2 + Poly(inosinic-cytidylic) acid 
(poly(I:C)) + CpG). These NPs were subsequently encapsulated in Eudragit FS-30D 
microspheres for oral administration to mice. These microparticles induced colorectal 
immunity and protection of animals against rectal and vaginal viral challenge. The 
induction of mucosal immunity and protection of antigens from gastrointestinal 
environment by PLGA NPs demonstrate their great potential for delivery of HIV 
vaccines (100). Furthermore, as mentioned before, nanosystems are able to develop 
multivalent vaccines carrying several antigenic substances simultaneously. Accordingly, 
Lamalle-Bernard et al. (2006) developed surfactant-free anionic PLA NPs acting as 
delivery system coadsorbing two vaccine antigens, HIV-1 p24 and gp120 proteins. 
Divalent PLA-p24/gp120 induced high antibody-mediated responses in mouse after SC 
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administration, suggesting its potential application as multivalent vaccine delivery 
systems (101). 
DermaVir (Genetic Immunity LLC, United States/Hungary) is a topical 
therapeutic vaccine in development (human phase II clinical trials) for patients being 
treated with antiretroviral drugs composed of HIV pDNA material encapsulated in 
mannosylated poly(ethyleneimine) (PEI) NPs. Dermavir is able to target mice epidermal 
LCs upon topical administration (102) allowing the induction of CD8
+
 Tc response and 
efficiently inhibiting and controlling Simian immunodeficiency virus (SIV) replication 
in infected rhesus macaques (103). 
 
1.7.1.2. HIV nanovaccine based on dendritic cells targeting 
 
Next generation of vaccines and immunotherapy technology is based on the 
ability to deliver antigens and immune stimuli to the most effective APCs, DCs, in a 
targeted and prolonged manner to develop a protective immune response against 
infection with subsequent activation of T-cell mediated immunity (104). DCs represent 
the sentinels of the immune system, residing in most peripheral tissues and bridging 
innate and adaptative immunity. Known as the most potent activators of naïve T cells, 
DCs are able to modulate the adaptative immunity by antigenic peptide presentation to 
CD4
+
 and CD8
+
 T lymphocytes through MHC class I and class II pathways, 
respectively (105). However, several complex processes including antigen transport to 
DC-rich areas across physiological barriers, DC binding, and antigen uptake, processing 
and presentation, as well as the immunogenicity and integrity of antigens influence 
immune responses.  
Biodegradable polymeric NPs have been designed to target DCs in new 
nanovaccine strategies, enhancing the antigen uptake process compared with soluble 
antigen alone. First of all, nanovaccine (foreign substance) induces an inflammatory or 
innate immune response, involving inflammatory mediator secretion. In particular, the 
secretion of MIP-1α in the peripheral tissues activates and recruits immature DCs, 
through their exclusive chemokine receptors, CCR1 and CCR5 (95, 106). Subsequently, 
immature DCs localized strategically in peripheral tissues (skin and mucosal surfaces) 
capture efficiently the nanovaccine and are activated to migrate into local secondary 
lymphoid tissues (spleen, lymph nodes and mucosal lymphoid system, mucosa’s and 
gut) to interact with naïve T cells for an adaptative response. This DC-maturation 
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process, induced by exposure to “danger signals”, is accompanied by a reduction of 
uptake capacity, acquisition of cellular motility with the development of characteristic 
dendrites, and migration to lymph nodes to efficiently present the antigen and further 
activate naïve T cells (107, 108). These issues are also accompanied by the down 
regulation of immature receptors and up regulation of CCR7, which directs DCs into the 
T cell area of lymph nodes through the production of CCR7 ligand, MIP-3β, by the 
resident DCs in T cell areas (109). In particular, DC maturation is induced by the 
recognition and interaction between highly conserved portions of molecular structures 
produced by pathogens, termed “danger signals” or pathogen associated molecular 
patterns (PAMP), and specific pattern recognition receptors (PRR), such as TLRs and 
C-type lectin receptors (CLRs) (110). Particularly, the interaction between TLRs and 
hydrophobic portions of ligands is also coupled to the expression of host-derived 
inflammatory molecules such as CD40 ligand (CD40L), TNF-α, IL-1, IL-6, and IFN-α 
initiating the adaptive immune response (111, 112). In addition, the contact with TLRs 
also induces cytokines and chemokines (IL-12 and IFN-γ) and co-stimulatory molecules 
(CD80 and CD86) mediators of innate immunity that are essential for the induction of 
adaptative response (113). In contrast, CLRs that recognizes various saccharides, such 
as D-mannose, L-fucose, and N-acetylglucosamine help in internalization for further 
processing and presentation by DCs (114). 
Following uptake process, antigens are released intracellularly and fragmented 
into peptides presenting at least 12 amino-acid by proteases in endosomes or 
phagosomes, which also contain high concentrations of MHC class II molecules 
(endolysosomal pathway). Before exported to the cell surface to bind specifically the 
receptors of CD4
+
 Th lymphocytes, antigenic peptides are loaded onto MHC class II 
molecules (115). On the other hand, antigenic peptides encapsulated into NPs can be 
processed into normally 8-9 amino-acid peptides and presented on cell surface by MHC 
class I molecules to activate CD8
+
 Tc lymphocytes, in a mechanism termed cross-
presentation only operated by DCs. The exact mechanism is poorly understood; 
however, two distinct routes have been proposed: i) in a transporter associated with 
antigen processing (TAP)-dependent pathway, antigen escapes from the endosomes into 
the cytosol, before lysosomal fusion, being degraded by cytosolic proteasomes into 
small peptides, which are then transported via TAP into the endoplasmic reticulum (ER) 
and loaded onto MHC class I molecules; ii) in a TAP independent manner favored by 
the low pH values in endosomal vesicles, the antigen is processed by endosomal acid 
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proteases. Once degraded, peptides are loaded onto the MHC class I molecules inside 
vesicles and exported to the cell surface (116). The question is: How MHC class I 
molecules enter into phagocytic vesicles? The first proposal is that MHC class I can be 
internalized into the phagocytic vesicles through membrane invagination during 
phagocytosis (117). Moreover, ER can fuse with phagocytic vesicles (118). 
Mature DCs are the most potent activators of naïve T cells (one DC can activate 
500 different T cells in 1 h, through the extension on dendrites) (119). Apart from the 
down regulation of DC endocytic activity and T cell receptor and co-receptor (CD3) 
stimulation by the peptide-MHC complex, a secondary co-stimulatory signal is 
necessary for the co-stimulation and expansion of naïve T cells. More specifically, the 
interaction between CD28 present on T cells and co-stimulatory molecules CD80 and 
CD86 on DCs enhances the production of the major T cell growth hormone, IL-2, 
which drives the clonal expansion of naïve T cells (120). In addition, the CD80 and 
CD86 molecular expression is activated through the interaction between CD40 on DCs 
and CD40L on naïve T cells, stimulating its activation. The strength of signal 
transduction is also influenced by other co-stimulatory molecules such as CD27, and 
secreted cytokines IL-12 and IFN-γ. Once activate naïve T cell are expanded and 
differentiated into effector and memory cells in a manner dependent of cytokines 
produced (121). 
Naïve CD4
+
 Th cells can be differentiated into Th2 cells, associated with the 
production of IL-4, IL-5, IL-10 and TGF-β, which can induce the activation of naïve B 
cells (122, 123). Mature B cells proliferate and differentiate into antibody-secreting 
plasma cells (IgG, IgA and IgE), helped by IL-5 and IL-6, or memory B cells. Upon the 
re-encountering with the same pathogen or antigen, memory B cells divide very rapidly 
and differentiate into antibody-secreting plasma cells (82). Additionally, associated with 
IL-12, IFN-γ and TNF-α, Th1 cells are produced and induce the stimulation of cytotoxic 
response to kill infected cells. In fact, naïve CD8
+
 Tc cells are differentiated into 
effector cytotoxic T lymphocytes (CTL) able to migrate to the inflamed peripheral 
tissue to eliminate virus-infected cells and release cytokines capable to decrease viral 
replication (124, 125). Particularly, the secreted IFN-γ may also promote the 
recruitment of cells from innate immune system, such as NK cells, granulocytes and or 
macrophages to eliminate infected cells (126). In addition, effector memory T cells are 
also developed, particularly from effector T cells. Notably, the immunological memory 
resultant from adaptative immunity and maintained by distinct populations of long-lived 
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memory cells is crucial to rapidly and effectively respond to pathogens (127). Figure 2 
illustrates the immune response described above.  
 
Figure 2 – The desired immune response elicited by a HIV vaccine is the combined action of 
CD8
+
 Tc cells and CD4
+
 Th cells. 
 
Moreover, as mentioned above, a potent cytotoxic response requires the presence 
of CD4
+
 Th cells to compensate for inadequate co-stimulation of naïve CD8
+
 Tc cells 
by APCs and to guarantee optimal activity of the induced CTL (128). HIV infection 
affects DCs function by the deregulation of cytokine network. More specifically, 
maturation of DCs and IL-12 secretion are typically reduced, thereby suppressing T cell 
response (129). Otherwise, IL-10 cytokine secretion is increased in infected individuals, 
thus limiting the activation and proliferation of T cells, rather inducing tolerance (130, 
131). Recent findings have also shown that IL-10 producing Treg cells (FoxP3-) can 
effectively suppress effector T-cell functions (132). 
Conceptually, particulate vaccine strategy mimicking the particulate nature of 
pathogens, including their size (nano- to micrometer range), has been employed being 
preferentially directed to DCs. Particle shape, size, surface charge and coating are also 
important physicochemical factors playing crucial roles in the interaction, 
internalization and processing of polymeric-nanosized vehicles by APCs, affecting the 
subsequent processing of antigen via MHC class I, MHC class II or cross-presentation 
pathways (133). Generally, immature DCs can internalize larger particles by either 
macropinocytosis or phagocytosis, while smaller particles are mainly taken up by 
receptor-mediated endocytosis (134). However, besides the ability inherent to polymer 
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NPs to act as an intrinsic “danger signal” inducing DC maturation and adaptative 
immune responses, they are not sufficiently strong to activate a sustained immunity. To 
increase targeting specificity and adjuvant effects, facilitating NPs uptake and DC 
maturation, surface can be functionalized with specific antibodies or ligands directed 
against DC-surface receptors. DCs can be targeted on lectin-like receptors, such as 
DEC-205 and DC-SIGN, using endocytosis ligands with a terminal sugar such as 
mannose, fucose and N-acetylglucosamine conjugated on NPs surface (135). Moreover, 
binding of specific adjuvants (e.g. TLRs ligands) with protein antigens in NPs is 
essentially to alert immune system, promoting a desired immune response, and allow 
the use of small doses of those compounds, limiting their toxicity (136). TLRs are the 
most studied class of PPRs to develop effective adjuvants and can be divided into 
surface bound receptors (TLR1, 2, 4, 5, 6) and intracellular receptors present in the 
endosomes (TLR3, 7, 8, 9) (137). Extracellular TLRs recognize bacterial invaders, but 
also fungi and some enveloped viruses, while intracellular TLRs recognize nucleic acids 
from viral or bacterial pathogens. CpG adjuvant can be incorporated into NPs acting 
directly on DC maturation by binding intracellular TLR9 (138). Also, the poly(I:C) 
adjuvant mimicking a double stranded RNA (dsRNA) can bind the TLR3. This receptor 
contributes to the initiation of immune responses against the induction of dsRNA 
replication by viruses, in infected cells (139). As well, monophosphoryl lipid A 
(MPLA) ligand can be delivered when associated with NPs to target TLR4 (84). It has 
been recently shown that IL-6 secreted by TLR4-activated DCs is capable of reversing 
the Treg suppressive effects, activating T-cell functions (140).  
Particulate delivery makes also possible simultaneous delivery of several TLR 
ligands in the same formulation. On the other hand, to enhance DC uptake, maturation 
and T-cell immunity, others ligands or cytokines can also be conjugated with the 
surface of polymer particles. Conjugation with DC-specific antibodies, anti-CD11c 
(myeloid marker) and anti-CD40, can also enhance the specificity of NPs for DCs in 
vivo, increasing the NP uptake and the subsequent immune response (141). In order to 
stabilize the conjugation process, the polymer “PEGylation” can be performed (142). 
Another important factor is premature antigen presentation on DC surface before 
reaching a lymph node, which can actually result in antigen tolerance. In this case, NP 
size can determine the antigen delivery to lymph-node-resident DCs instead of only 
peripheral DCs, providing a more-potent immunostimulation. In this case, the 
internalization and antigen processing is attained in lymph nodes due to a fraction of 
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resident immature DCs (143). Small NPs (<100 nm) are directly transported to lymph 
nodes, into the lymphatic system by interstitial flow; larger NPs (>500 nm) are 
predominantly internalized by skin DCs (dermis, epidermis and to a lesser extent 
subcutis), draining subsequently to the lymph nodes; and intermediate nanovaccines 
(100-500 nm) present both pathways (44). Studies have shown that NPs within viral-
sized range, are preferentially internalized by DCs, whereas those presenting 
dimensions similar to bacteria are preferentially ingested by macrophages (144). 
According to the surface charge, cationic NPs display ionic attraction with negatively 
charged cell surface, facilitating the binding and particle internalization (145). Since 
DCs recognize nanovaccine as exogenous antigens, the MHC class II pathway is 
followed preferentially than MHC I molecules via cross-presentation. However, the 
induction of a strong and broad CD8
+
 Tc cell response is a prerequisite for a therapeutic 
vaccine. In this context, to improve cross-presentation, promoting the antigen escape 
from endosomes into the cytosol, polymeric NPs based on amphiphilic PG were 
developed (146). Furthermore, the efficacy and nature of the immune response is also 
influenced by the route of administration. Polymeric NPs administered ID or SC were 
efficiently internalized by DCs (147). Nanovaccine size has a major impact when 
administered into the skin. However, retention in the skin is a drawback. Accordingly, 
direct administration into the lymph node might offer an attractive route. Otherwise, 
injection into the blood is less size dependent. It is important to highlight that the time 
period at which antigen and adjuvant reach DCs is crucial, affecting the immune 
outcome. Tolerance may be induced if the maturation stimulus is given too late after 
antigen capture by DCs. On the other hand, antigens will not be efficiently presented if 
they reach already mature DCs (84). In summary, the specific targeting of particles to 
DCs may not only enhance efficacy but also the specificity of interaction. 
 
1.7.1.3.  HIV nanovaccine based on peptide HIV-1 fusion inhibitors 
 
Generation of broadly-neutralizing antibodies to prevent (new) infections of host 
cells is a major purpose for HIV-1 vaccine development. Consequently, the advance of 
new immunogens which elicit bNAbs, capable of protecting against several different 
strains of HIV, has stimulated the HIV vaccine research, for prevention and treatment 
(148). As a result, several conformational changes involved in the interaction between 
viral envelope glycoproteins and host receptors, resulting in the entry of HIV into host 
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cells, has received special attention (149). There are three categories of entry inhibitors: 
(1) interference with the binding of the HIV-1 gp120 to CD4 receptors is attained by 
attachment inhibitors; (2) inhibition of the interaction between gp120-CD4 complex and 
coreceptor (CCR5 or CXCR4) is achieved by coreceptor inhibitors; and (3) inhibition of 
fusion between viral and cellular membranes is performed by fusion inhibitors (150). 
Despite all the steps of viral entry being considered important for HIV-1 drug design, it 
is preferable to develop anti-HIV drugs targeting viral proteins (gp120 and gp41) rather 
than host cell molecules (CD4, CCR5 and CXCR4), because binding the cellular 
molecules might cause toxic or adverse effects interfering with their normal functions 
(150). In this regard, the investigation of different epitopes in the HIV envelope 
glycoproteins, blocked by new discovered bNAbs, as potential targets for vaccine 
development, has been explored (151). In recent years, new antiretroviral inhibitors 
belonging to the third class of anti-HIV-1 drugs, have been developed. The fusion 
inhibitors target an earlier HIV-1 life-cycle process, specifically components of the viral 
entry pathway, preventing and stopping HIV-1 infections more efficiently than RTI and 
PI. Peptide fusion inhibitors derived directly or engineered from HIV-1 gp41 NHR or 
CHR sequences can be made by peptide synthesis or produced as recombinant proteins 
or peptides, depending on their length and in vivo stability. Generally, the interference 
with the fusion process is achieved by the formation of unproductive 6HBs with HIV-1 
gp41 NHR or CHR counterparts, inhibiting virus-target cell fusion and preventing HIV-
1 infection. However, CHR peptide fusion inhibitors are the most exploited, showing 
greater anti-HIV potency than NHR peptides (152). 
Since 2003, T20 (enfuvirtide, Fuzeon
®
), initially termed DP178 and identified by 
Wild’s group (early 1990s), was the first HIV fusion inhibitor approved by the FDA for 
the treatment of HIV-infected individuals and AIDS patients (153, 154). T20 is a 36-
amino acid linear peptide that mimics the sequence of the CHR domain in HIV-1 gp41 
(a.a 127-162 in gp41 or a.a 638-673 in gp160 precursor) (150, 155). Its mechanism of 
action seems to be different of the established interaction model for HIV-1 peptide 
fusion inhibitors. T20 may interact either with gp41 NHR or the target cell membrane, 
blocking the formation of the 6HB structure and preventing viral fusion and HIV-1 
infection (6, 156). Enfuvirtide presents high solubility under physiological conditions 
and anti-HIV-1 activity in the nanomolar range. It inhibits HIV-1 replication in human 
cell types such as mature and immature DCs, and macrophages, with values of IC50 
(concentration required for 50% inhibition) ranging from 0.0018-0.853 μg/mL (157). 
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However, T20 is only used as a salvage therapy in HIV-1 infection, being injected 
parenterally (subcutaneously) twice daily due to the poor orally bioavailability (158). 
Additionally, the major problem is T20-resistant HIV-1 mutations mostly found in NHR 
domain of gp41, which decrease the binding efficiency between T20 and its target gp41 
NHR. To overcome T20 resistance, a new generation of peptide fusion inhibitors was 
developed. In addition, increase the helical content of peptide fusion inhibitors, using 
salt bridges and helix-enhancing amino acids; increase their binding efficiency for 
NHR; as well as their in vivo stability, have been shown to improve their anti-HIV-1 
potency (159). Accordingly, T1249 is a more potent second generation HIV-1-fusion 
inhibitor composed of 39 amino acids and derived from CHR consensus sequences of 
HIV-1 gp41 (11). To combat T20-resistant virus, T1249 contains conserved amino acids 
from SIV and HIV-2 sequences, as well as, an alanine substitution and a salt bridge to 
increase the helical content (160). T1249 was tested in treatment-experienced HIV-1 
infected patients presenting a reduction on viral loads, non-severe side effects and 
enhanced anti-HIV-1 activity against T20-resistant virus (161). 
Despite all those positive results, these peptides present crucial weaknesses 
including high degradation by proteases, poor oral availability, reactions associated with 
administration in the majority of patients, and complex and highly expensive 
manufacturing procedure. Therefore, the development of polymeric nanocarriers is 
essential for the transport and protection of these peptide fusion inhibitors. Moreover, 
the complexity of immunological events related to infectious diseases clarifies that the 
encapsulation of both peptides into polymeric NPs developing a divalent vaccine can be 
a new promising strategy for worldwide control of HIV.   
 
1.7.2. PLGA nanoparticles as promising HIV vaccine delivery systems 
 
PLGA is a biodegradable synthetic polymer approved by the FDA for human use, 
due to its favorable properties such as good biocompatibility, biodegradability and 
mechanical strength. The hydrolysis of PLGA results in lactic and glycolic acid 
monomers that are metabolites well tolerated in the human body, and depends mainly 
on the molecular weight, hydrophilicity and crystalinity of the polymer (162). PLGA 
has been used to a greater extent than PLA due to its higher degradation rate. The 
smaller molecular weight, the higher hydrophilicity and less crystalinity of PLGA 
polymers attained with higher proportions of glycolic acid (more hydrophilic and 
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amorphous) and less lactic acid (more hydrophobic and crystalline), tend to increase the 
rate of polymer degradation. Exceptionally, due to its amorphous nature, PLGA co-
polymer with 50:50 glycolic:lactic acid ratio is more susceptible to hydrolysis and 
degradation (half-life about 2 weeks) among PLGA polymers with lower or higher 
glycolic:lactic acid ratios (163). Besides biomedical applications, PLGA co-polymer has 
been employed to fabricate NPs as delivery systems applied to different pathologies, 
particularly in cancer world. PLGA NPs encapsulating tumor-associated antigens 
(TAAs) either alone or associated with adjuvants (such as TLR ligands), as well as 
tumor lysates, have been tested as cancer vaccines. In order to restore 
immunocompetence in cancer patients, an inhibitor of signal transducer and activator of 
transcription (STAT)-3 (activated in tumor cells inducing immunosuppression) has been 
encapsulated into PLGA NPs (164). PLGA-based NPs are also currently under 
investigation for applications in cancer therapy, such as chemotherapy and gene 
therapy. PLGA NPs combined with paclitaxel (mitotic inhibitor used in the treatment of 
various cancers) have demonstrated in vitro and in vivo greater cytotoxic effects than 
paclitaxel alone (165). PLGA NPs loaded with plasmid coding for siRNA sequence 
targeting methyl-CpG binding domain protein (MBD)-1 showed to be taken up in vitro 
by pancreatic cancer cells up to 30%, leading to cell growth inhibition and inducing 
tumor cell apoptosis (166). PLGA has also been used as non-invasive molecular 
imaging systems for cancer diagnosis and imaging. PLGA nanocarriers were used to 
transport superparamagnetic iron oxides for Magnetic Resonance Imaging (MRI), 
improving the imaging effects (167). 
In order to target inflammation sites and avoid long-term treatment, PLGA NPs 
were shown to deliver and release sustainably anti-inflammatory drugs into a target site. 
PLGA NPs encapsulating tacrolimus increased drug amounts in inflamed areas, whereas 
free tacrolimus was found in high concentrations in healthy tissues of two different rat 
colitis models (168). For rheumatoid arthritis therapy, the direct injection of PLGA NPs 
containing betamethasone sodium phosphate (BSP) in arthritic joints of rabbits showed 
a sustained release and a prolonged pharmacological efficacy than BSP administered as 
an aqueous solution (169). In addition, the oral administration of PLGA NPs 
encapsulating curcumin enhanced therapeutic effect in cystic fibrosis model mice, as 
compared to non-encapsulated curcumin (170). 
The incorporation of bioactive molecules, which stimulate cell migration, 
proliferation or induce cell differentiation, such as growth and neurotrophic factors, into 
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PLGA NPs has been a promising tool in regenerative medicine. PLGA NPs loaded with 
fibroblast growth factor (FGF)-2 increased the total number of large and moderate 
diameter arterioles, as well as a marked luminal expansion of both the pre-existing 
collateral arteries and the transverse arterioles in ischemic mouse hind-limb adductor 
muscles (171). 
Additionally, PLGA has also been investigated for the treatment of cardiovascular 
diseases. PLGA-based systems have been employed to develop engineered grafts used 
in arterial replacement when cardiovascular tissue is too damaged (172). 
Insulin-loaded PLGA NPs have been extensively studied in the treatment of 
diabetes mellitus (type I). Their administration in vivo considerably decreased the blood 
glucose levels of diabetic mices (173). 
The development of alternative treatments against infection has also involved the 
preparation of PLGA-based NPs. The development of antibiotic-loaded PLGA NPs has 
improved the treatment of bacterial infections. Nafcillin-loaded PLGA NPs 
demonstrated their potential use for the treatment of osteomylitis by significant 
reduction or destruction of intracellular Staphylococcus aureus infecting osteoblasts 
(174). Moreover, PLGA NPs loading Hepatitis B core antigen induced a stronger 
cellular immune response in a murine model (175, 176). PLGA-based nanocarriers 
encapsulating a version of the West Nile virus envelope protein elicited a robust cellular 
immune response and protection against West Nile encephalitis in a mouse model, 
being effectively endocytosed by immune cells and thus leading to proinflammatory 
cytokines secretion (177). In particular case of HIV infection, PLGA NPs have been 
employed particularly for prophylaxis. HIV prophylaxis has explored the use of PLGA 
NPs to deliver antiretroviral drugs and siRNA. Ham et al. (2009) engineered PLGA NPs 
containing PSC-RANTES (CCR5 chemokine receptor inhibitor) that demonstrated 
higher uptake by human ectocervical cells, as compared to nonencapsulated inhibitor, in 
ex-vivo studies. Furthermore, these NPs could achieve a critical component of the HIV 
infection - the basal layer of the cervical epithelium (178). PLGA NPs containing 
siRNA directed to specific genes relevant to Herpes Simplex Virus type 2 (HSV-2) 
infection were developed and evaluated for their in vitro and in vivo efficacy in 
comparison to siRNA-lipoplexes. siRNA-loaded PLGA NPs showed in vitro 
significantly higher gene silencing, which was further confirmed in vivo 7 days after  
treatment; induced higher survival when intravaginally administered to mice, before and 
after lethal HSV-2 challenge and disease progression, observed for 28 days; and did not 
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show relevant inflammation and epithelial damage in the vaginal mucosa after the 
treatment (179). The development of pH-sensitive PLGA NPs for vaginal delivery of 
tenofovir was completed with the addition of Eudragit S100, a pH-sensitive polymer 
that dissolves at pH 7.4. NPs were well tolerated by vaginal epithelial cells and 50% 
internalized by those cells after 24 h of incubation. These NPs released minimal amount 
of drug in simulated vaginal fluids (pH 4.5) and higher amount of drug in the simulated 
seminal fluid (pH 7.6), due to presence of Eudragit S100. The drug release was 
sustained for 24 h due to presence of PLGA polymer. Problems of tenofovir 
nanoencapsulation have been reported due to its extreme hydrophilicity, not being 
achieved entrapment efficiency (EE) greater than 40 %. This is a major challenge that 
still needs to be overcome (180). In the field of prophylaxis, a combination of 
antiretroviral drugs has gained success mainly to avoid drug resistance. Thermosensitive 
vaginal gel (liquid at room temperature and very viscous at 37 ºC), containing 
raltegravir-(RAL, integrase inhibitor) and efavirenz-(EFV, non-nucleoside reverse 
transcriptase inhibitor) loaded PLGA NPs (RAL+EFV–NPs), was developed for pre-
exposure prophylaxis of HIV, using a combination of Pluronic F127 and Pluronic F68. 
RAL+EFV–NPs did not cause any cytotoxicity to HeLa cells for 14 days and have 
shown a sustained intracellular release of both RAL and EFV. Despite the intracellular 
levels of EFV above EC90 (90.3 ng/mL) for 14 days, RAL intracellular concentrations 
disappeared within 6 days. Fluorescent NPs fabricated similarly to the RAL+EFV–NPs 
demonstrated rapid transfer from the gel to transwell membrane and were taken up by 
HeLa cells within 30 min. Summarizing, thermosensitive vaginal gel composed of 
RAL+EFV–NPs demonstrated antiretroviral potential for long-term prophylaxis of 
HIV-1 transmission (181). 
Despite the ability of PLGA NPs as drug delivery systems for HIV prophylaxis, 
and their extensive use in cancer vaccines, namely the study previously described and 
developed by Zhu et al. (2012) demonstrated the applicability of these particulate 
delivery systems, using PLGA NPs as HIV vaccine carriers. PLGA NPs mimicking 
viral particles represent pharmaceutically promising systems for in vivo antigen delivery 
within HIV vaccine field design. PLGA NPs provide a continuous and prolonged 
release of entrapped cargo for long periods of time, avoiding the risk of tolerance and 
the need for several boosting administrations (182). Moreover, several antigens and 
adjuvants can be encapsulated into the same PLGA NPs formulation (183). PLGA NPs 
seem to have the particular ability to rapidly escape the endolysosomal pathway, being 
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released into cytoplasm reaching the MHC class I pathway, after being internalized by 
DCs (184). PLGA-based nanosystems have been also shown to be able to induce DC 
maturation as well as broad and potent humoral and cellular immune responses, 
entrapping low doses of antigens and adjuvants (185). Furthermore, despite PLGA NPs 
adjuvant effects, its surface can be easily decorated with several immunomodulators and 
endocytosis ligands (186, 187). Additionally, PLGA can be further modified with 
hydrophilic moieties like hydrophilic and non-ionic polymer poly(ethylene glycol) 
(PEG) to form NPs with increasing lifetime in vivo and higher stability in 
gastrointestinal fluids (188). All these evidences and the studies reported above seem to 
confirm the possible utility of PLGA to produce nanodelivery systems for the promising 
development of anti-HIV vaccines. 
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2. Goals 
 
AIDS remains a worldwide health threat, with more than 34 million people 
infected at the end of 2010. Despite the progress achieved on HIV prevention, detection 
and treatments, which significantly prolonged the life of HIV infected people, the 
complete erradication of this disease was not yet fully achieved. The main goal of 
several research groups worldwide has been the identification of new immunogens able 
to elicit the production of reactive HIV neutralizing antibodies that seems to be crucial 
for the development of an effective immune response against this infection agent. 
Polymeric NPs are a promising strategy to deliver antigens and adjuvants to 
APCs, as they have the capacity to overcome cellular barriers and to target specific cells 
and organelles. DCs, considered highly specialized APCs, after maturation, can elicit 
effective humoral and cellular immune responses throught the induction of virus-
specific neutralizing antibodies and cytotoxic effect, preventing HIV infection at the site 
of viral entry and impairing the dissemination of the virus, respectively.  
 This project aims to develop and characterize different types of PLGA and 
PLGA-PEG NPs-based HIV-1 vaccine designed to deliver incorporated HIV-1 gp41 
peptides to DCs to be ultimately used to stimulate effective immune responses with the 
production of neutralizing antibodies that will promote the complete prevention of this 
infection and, enventually, contribute for the treatment of this disease. 
The main tasks designed for this project include (i) the production and 
optimization of NPs; (ii) the physicochemical characterization of nanoparticulate 
candidates; (iii) the entrapment of antigens in PLGA-based nanoparticulate systems; 
(iv) the assessment of HIV-1 peptide integrity after entrapment; (v) the evaluation of 
cytotoxic effect of NPs in targeted DCs; (vi) the in vitro study of the uptake of 
nanocarriers by targeted DCs and characterization of their cellular trafficking. 
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3. Materials and Methods 
 
3.1. Materials 
 
Solutions were prepared from analytical grade reagents using Millipore Milli-Q 
ultrapure water (resistivity ≥ 15.0 MΩcm). 
Poly(vinyl alcohol) (PVA, molecular weight (Mw) 13,000-23,000 Da), Pluronic
®
 
F127 (PL, Mw 12,600 g/mol), glycol chitosan (GCs), albumin from chicken egg white 
(ovalbumin or OVA, Mw 45,000 Da), bovine serum albumin (BSA, Mw 66,000 Da), 
phosphate buffered saline (PBS, 0.01 M pH 7.4), calcium chloride (CaCl2), magnesium 
chloride (MgCl2), sucrose, N,N,N',N'-tetramethylethylenediamine (TEMED), glycine, 
glycerol, ammonium persulfate (APs), sodium dodecyl sulphate (SDS), trizma
®
 base, 
coomassie brilliant blue G 250, Triton X-100, paraformaldehyde, poly-L-lysine solution 
(PLL), sodium phosphate dibasic (Na2HPO4), sodium phosphate monobasic (NaH2PO4), 
sodium chloride (NaCl) and Mowiol
®
 4-88 (PVA, Mw 31,000 Da) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). PLGA Resomer
®
 RG 502 (lactide:glycolide 
50:50, Mw 7,000–17,000 g/mol) and PLGA-co-PEG Resomer
®
 RGP d50155 (PLGA-
PEG, Diblock, 15 % PEG with 5,000 Da) was purchased from Boehringer Ingelheim 
GmbH (Ingelheim, Germany). Acrylamide/bisacrilamide and SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) Mw marker (Precision Plus Protein
TM
 standards 10-250 
kDa) were supplied by Bio-Rad (Hercules, CA, USA). Bromophenol blue, 
dichloromethane (DCM), hydrochloric acid (HCl), acetic acid and methanol were 
purchased from Merck (Darmstadt, Germany). The MicroBCA
TM
 protein assay kit was 
supplied by Thermo Fisher Scientific Inc. (Rockford, IL, USA). 
HIV-1 antigens, T20 and T1249 peptides, were kindly provided by Prof. Nuno 
Taveira from iMed - Research Institute for Medicines, Faculty of Pharmacy, 
Universidade de Lisboa. 
Rhodamine 6G derivative-grafted PLGA (Rho-grafted PLGA) polymer was 
synthesized as described by Freichels et al. (2011) and kindly provided by Prof. Carlos 
Afonso from iMed - Research Institute for Medicines, Faculty of Pharmacy, 
Universidade de Lisboa (189). 
Murine immature bone marrow dendritic cells (BMDCs, JAW SII, ATCC
®
CRL-
11904
TM
) was purchased from American Type Culture Collection (ATCC, Manassas, 
VA, USA).  
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PBS sterile (0.01 M pH 7.4, [-]CaCl2, MgCl2), RPMI 1640 + Glutamax
TM
, heat 
inactivated fetal bovine serum (FBS), granulocyte-macrophage colony stimulating 
factor (GM-CSF), trypsine EDTA 0.25 %, HEPES, sodium pyruvate, 
penicillin/streptomycin (PEST) 10,000 U/mL/10,000 µg/mL, β-mercaptoethanol and 
Trypan-Blue stain were purchased from Gibco
®
 Invitrogen (Life Technologies, Paisley, 
United Kingdom). 
Cell culture disposable material as cell culture flasks, cell lifters, 24- and 96-well 
plates were purchased by Corning
®
 (Life Technologies, Paisley, United Kingdom). 
Anti- EEA1 and anti-calnexin immunofluorescence rabbit anti-mouse antibodies 
for confocal microscopy were acquired from Novus Biologicals (Littleton, CO, USA). 
Goat anti-rabbit IgG Alexa Fluor 488
®
 antibody and AlamarBlue
®
 reagent were 
purchased from Life Technologies (Carlsbad, CA, USA). 
 Dulbecco’s PBS (DPBS, 0.01 M pH 7.4, [+] 0.9 mM CaCl2, 0.45 mM MgCl2) 
was prepared by adding appropriate amounts of CaCl2 and MgCl2 to PBS.    
 
3.2. Methods 
 
3.2.1. Preparation of nanoparticles 
 
OVA (model antigen) and HIV-1 antigens, T20 and T1249 peptides, were 
entrapped in different polymeric NPs using a double emulsion (water-in-oil-in-water 
(w/o/w)) solvent evaporation method, also named double emulsion method, as reported 
elsewhere, with modifications (190). Briefly, the internal aqueous phase (IP) was 
composed by 10 % (w/v) PVA or 8 % (w/v) PVA/0.1 % (wGCs/wpolymer) GCs aqueous 
solutions, in which OVA (250 µg) or HIV-1 peptides (200 µg, or 100 µg of each one for 
co-entrapment) were dissolved for HIV antigen-loaded NP. This IP was then emulsified 
with an organic solution (10 mg polymer, PLGA or PLGA-PEG in DCM), under 
continuous sonication at 70 W, for 15 s, using an ultrasonic processor (XL 2015 
Sonicator
®
 Ultrasonic processor, Misonix, Inc, Farmingdale, NY), leading to the single 
w/o emulsion. 
In order to form the double emulsion, a 1.25 % (w/v) PVA solution was added to 
the single w/o emulsion and sonicated under the same conditions. The obtained w/o/w 
emulsion was added dropwise to the external aqueous phase (EP) (0.25 % (w/v) PVA or 
0.125 % (w/v) PL), and left under magnetic stirring for 1 h at 37 ºC, allowing DCM 
evaporation and NPs formation. The formulation details are shown in Table 1. 
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Table 1 – Composition of plain and antigen-loaded PLGA or PLGA-PEG nanoparticles. 
 
NPs were thereafter separated from the preparation media and washed with 
millipore ultrapure water, in order to remove the excess of surfactant and non-entrapped 
antigen, through three centrifugations, at 22,000 x g, 4 °C, for 45 or 20 min (Beckman 
Coulter Allegra 64R High Speed Centrifuge) for formulations with or without GCs, 
respectively. NPs were then resuspended in DPBS (20 mg/mL) and preserved at 4˚ C 
for following in vitro experiments.  The yield (η, % (w/w)), was calculated according to 
Equation 1. Formulation batches were frozen overnight and freeze-dried under vacuum, 
for 24 h (Freezone 1 Labconco
®
 Lyophilizator, Kansas City, MO, USA), after 
resuspension in lyoprotectant 10 % (wsucrose/wpolymer) sucrose aqueous solution. 
η     
                              
                                
                                                 Equation 1 
After each centrifugation, supernatants were recovered and kept at 4 ºC, or frozen at -20 
ºC until future analysis. Plain NPs were formulated using the same protocol, without the 
dissolution of HIV-1 antigens. Fluorescent rhodamine-labeled NPs (NPs-Rho) for 
confocal microscopy were formulated by replacing one tenth of the PLGA-PEG mass 
by Rho-grafted PLGA polymer.  
3.2.2. Physicochemical characterization of nanoparticles 
 
3.2.2.1. Size and zeta potential analysis 
 
A Zetasizer Nano ZS equipment (Malvern Instruments, Worcestershire, UK) was 
used to determine the mean NP size (Z-Average, Z-Ave) and polydispersity index (PdI) 
by Dynamic Light Scattering (DLS) in combination with cumulative analysis. The same 
equipment allowed the determination of NP surface charge (zeta potential, ZP) by Laser 
Doppler Electrophoresis (LDE) in combination with Phase Analysis Light Scattering 
FORMULATION 
MATRIX 
POLYMER 
INTERNAL PHASE EXTERNAL PHASE 
Polymer_PVA_plain 
PLGA 
or PLGA-PEG 
10 % (w/v) PVA 
0.25 % (w/v) 
PVA Polymer_PVA_antigen Antigen/10 % (w/v) PVA 
Polymer_GCs_plain 
PLGA 
or PLGA-PEG 
8 % (w/v) PVA+0.1 % (w/w) GCs 
0.25 % (w/v) 
PVA Polymer_GCs_antigen Antigen/8 % (w/v) PVA+0.1 % (w/w) 
GCs 
Polymer_PL_plain PLGA 
or PLGA-PEG 
10 % (w/v) PVA 
0.125 % (w/v) PL 
Polymer_PL_antigen Antigen_10 % (w/v) PVA 
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(PALS), at 25 ºC. In brief, each batch of NP suspension (20 mg/mL) was diluted twenty 
and two hundred times, in DPBS. The diluted working suspension was primarily 
introduced into a cuvette to evaluate the Brownian motion of NPs based on laser light 
scattering, measuring size and PdI. Thereafter, the same suspension was inserted into an 
electrode specific cell for electrophoretic mobility determination (ZP). Because ZP is 
extremely dependent on pH and ionic strength of the dispersant and NP concentration, 
measurement and working conditions were always maintained constant to obtain 
comparable results.                
Each dilution was measured in triplicate where, each zeta potential data 
correspond to 100 measurements, while for size and PdI data it represents 13-16 
readings. Each formulation was also prepared in triplicate, resulting in three different 
batches for the same particle composition.      
 
3.2.2.2. Surface morphology analysis 
 
The surface morphology of NPs was characterized by Atomic Force Microscopy 
(AFM), using a Nanoscope IIIa Multimode AFM produced by Digital Instruments 
(Veeco). Samples were prepared by depositing a drop of final colloidal suspension onto 
freshly cleaved mica at room temperature, for 15 min, and then carefully dried with pure 
N2. All measurements were carried out using tapping-mode AFM with etched silicon 
tips (~ 300 kHz), at room temperature, obtaining topography and phase images.  
 
3.2.3. Antigen loading analysis 
 
The entrapment efficiency (EE, % (w/w)) is the percentage of entrapped antigen 
into the polymeric matrix of NPs over the initial amount of loaded antigen (Equation 2). 
On the other hand, the loading capacity (LC, µg/mg) is defined as the antigen amount 
(µg) present per mg of NPs (Equation 3).  
The EE (% (w/w)) and LC (µg/mg) of model antigen, OVA, were determined 
indirectly by the colorimetric MicroBCA
TM
 protein assay (191) and High Performance 
Liquid Chromatography (HPLC), using the supernatants obtained  after washing and 
centrifugation steps, performed for each batch of NPs. 
Regarding the protein quantification by the MicroBCA
TM
 assay, triplicate aliquots 
of each supernatant were transferred to a polystyrene 96-well plate (Greiner Bio-One, 
Frickenhausen, Germany), including the supernatants of plain NPs to be used as 
controls, by subtracting the contribution of polymers and surfactants to absorbance. A 
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calibration curve using OVA aqueous solution in the concentration range of 2.5–40 
μg/mL was prepared in triplicate, for each plate assay. Absorbance values were read at 
560 nm, using a microplate reader (FLUOstar Omega, BMG Labtech, Durham, NY, 
USA), after incubation with the MicroBCA
TM
 reagent at 37 °C, for 2 h. 
OVA was also indirectly quantified by HPLC. Chromatographic analyzes of 
supernatants were performed using a Beckman System Gold: UV-vis detector 
(Beckman 166), Beckman 126 solvent module and a Midas autosampler. Samples (20 
µL) were injected onto a Shodex PROTEIN KW-803 series column (8.0 mm ID x 300 
mm, 5 µm particle size, 300 Å pore size) and eluted with sodium phosphate buffer (0.05 
M pH 7.0) plus NaCl (0.3 M), at room temperature (run time: 20 min, flow rate: 1 
mL/min). OVA elution from each supernatant was monitored at 220 nm by 
spectrophotometric analysis and their amount calculated using the standard calibration 
curve obtained as mentioned above. Each curve was generated by known concentrations 
of OVA, prepared using the first supernatant recovered after centrifugation of plain 
NPs. This calibration curve demonstrated to be linear over the range of 0.5–10 µg/mL 
of OVA, presenting a correlation coefficient r
2≥0.99.  
The EE (% (w/w)) and LC (µg/mg) of HIV-1 antigens were indirectly quantified 
by the intrinsic fluorescence assay of tyrosine, tryptophan and phenylalanine 
aminoacids present in T20 and T1249 peptides. Similarly, supernatants were placed in 
triplicate into a black polystyrene 96-well plate (Perhinelmer
®
, Walthman, MA, USA), 
including those obtained for plain NPs. Calibration curves for T20, T1249 or co-
entrapment were prepared in triplicate, using peptide aqueous solutions in a 
concentration range of 2.5–40 μg/mL for each plate assay. For NPs with co-entrapped 
antigens, the amount of T20 and T1249 was calculated as a total amount, using a 
calibration curve prepared with a 1:1 mixture of both peptides. Fluorescence intensity 
was measured at 280 nm and 340 nm of absorbance or emission wavelengths, 
respectively, using a microplate reader (POLARstar OPTIMA, BMG Labtech, Durham, 
NY, USA). Plates were maintained at 4 ºC and protected from light until measurement. 
EE (% (w/w)) and LC (μg/mg), for all studied antigens, were calculated as follows 
(Equations 2 and 3):  
 
       
                                                               
                         
           Equation 2 
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         Equation 3 
 
3.2.4. Cell culture conditions 
 
Murine immature BMDCs were propagated in RPMI 1640 + Glutamax
TM
 
supplemented with 10 % (v/v) FBS, 1 % (v/v) PEST, 50 μM β-mercaptoethanol, 10 mM 
HEPES, 1 mM  sodium pyruvate and 5 ng/mL GM-CSF, in a humidified incubator with 
5 % CO2, at 37 °C, using 75 cm
2
 flasks (Corning
®
, NY, USA). Medium was replaced 
twice a week and cells subcultured at a 1:2 ratio when log phase of growth was 
achieved. BMDCs have a combination of non-adherent and adherent cells. For BMDCs 
subculture, non-adherent cells with old medium were transferred to a 75 cm
2
 sterile 
Falcon
®
 flask. Adherent cells were washed with 2 mL of PBS sterile, collected by 
tripsinization using 4 mL of trypsin EDTA 0.25 % at 37 °C, 5 % CO2, for 3 minutes, 
and transferred to the same Falcon
®
 flask of non-adherent cells. After centrifugation at 
250 x g for 5 min using an Eppendorf
®
 5430 R centrifuge, supernatant was removed and 
the BMDCs pellet resuspended in 5 mL of fresh medium. Cell counting was performed 
on a haemocytometer (Neubauer, Brand, Germany), using Trypan-Blue stain. 
 
3.2.5. In vitro cell viability assay 
 
In order to evaluate quantitatively the cytotoxic effect of NPs in murine immature 
BMDCs, metabolic activity of mitochondrial dehyrogenase was measured by using the 
AlamarBlue
® 
assay. Cells were seeded at a density of 1.5x10
4
 cells/100 μl/well in 96-
well plates and incubated overnight, in a humidified incubator with 5 % CO2, at 37 °C. 
Thereafter, BMDCs were treated with different concentrations of the three groups of 
plain PLGA-PEG NPs (0.125, 0.25, 0.5 and 1 mg/mL). Cells exposed to PBS or 0.05 % 
(v/v) Triton X-100 instead of NPs, were used as negative or positive controls, 
respectively. After 21, 45 and 69 h of incubation in a humidified incubator, 
AlamarBlue
®
 reagent was added at 10 % (v/v) and incubated for 3 h. After 24, 48 and 
72 h of total incubation time, absorbance values of AlamarBlue
®
 reagent were measured 
at 570 nm (AlamarBlue reduced form, pink)  and 600 nm (AlamarBlue oxidized form, 
blue), using a microplate reader (FLUOstar Omega, BMG Labtech, Durham, NY, 
USA). Each assay was performed in hexaplicate (n=6) and each NPs formulation was 
evaluate in triplicate (N=3). 
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Cell viability (%) was normalized and plotting versus NP concentration. Higher 
values are correlated to an increased total metabolic activity of cells or to the presence 
of phenol red in the growth medium which, according to manufacturer instructions, 
shifts the values approximately 0.03 units higher. The relative cell viability related to 
control wells was determined by the following equations:  
 
                   
                               
                                         
                  Equation 4 
 
    
                                     
                                     
                                                       Equation 5 
 
3.2.6. Peptide integrity assessment  
Evaluation of peptide integrity was determined by SDS-PAGE. The SDS-PAGE 
gel was composed by a stacking gel (4.7 % (w/v) acrylamide) and a resolving gel (16 % 
(w/v) acrylamide), prepared with acrylamide:bisacrylamide solutions. NP suspensions 
and peptide standard solutions (control) were mixed with the SDS-containing loading 
buffer (LB) achieving the final concentrations of 15 mg/mL and 0.75 mg/mL for NPs 
and each of the peptides (T20 and T1249), respectively. Afterwards, samples were 
centrifuged at 1000 x g for 5 minutes, incubated at 100 °C for 10 minutes and cooled to 
room temperature before being loaded into the gel (20 μl). A molecular weight marker 
with proteins of known molecular weight, ranging from 10-250 kDa (Mw markers, Bio-
Rad, Hercules, CA, USA) was loaded into the gel (10 μl), providing a reference to 
determine the mass of peptides entrapped into NPs. Electrophoresis was performed 
using a running buffer composed by 0.025 mM (w/v) trizma, 0.192 M (w/v) glycine and 
0.1 % (v/v) SDS,  applying a constant voltage of 150 V at room temperature, for 90 min 
using a Bio-Rad 300 Power pack
TM
 electrophoresis system (Bio-Rad, Hercules, CA, 
USA). To reveal peptide bands, the resolving gel was stained with a coomassie blue 
solution containing 0.125 % (w/v) coomassie blue G, 10 % (v/v) acetic acid and 50 % 
(v/v) methanol. Gel was further distained using a solution of 5 % (v/v) acetic acid and 7 
% (v/v) methanol.  
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3.2.7. Cell uptake and intracellular trafficking studies 
 
For qualitative uptake and intracellular trafficking studies based on confocal 
microscopy imaging, BMDCs (2×10
5
 cells/400 µL/well) were seeded in 24-well plates, 
on coverslips previously coated with PLL, and incubated overnight in a humidified 
incubator with 5 % CO2, at 37 °C, allowing cells to become adherent. Thereafter, 
without removing the medium, fluorescent PLGA-PEG_GCs_plain NPs containing 
Rho-grafted PLGA were added at 500 µg/mL and incubated for 1, 5 and 20 h. After this 
period, cells were washed twice with PBS. In order to fixe and then permeabilized cells 
for antibody  staining, without destroying cell structures, 4 % (w/v) paraformaldehyde 
in PBS (pH 7.4) and 0.2 % (v/v) Triton X-100 were added separately for 10 minutes, at 
room temperature, with removing and washing (3x with PBS) steps before each 
addition. To prevent unspecific binding of antibodies (Abs) and thus minimize the 
background, 2 % (w/v) BSA blocking solution was added to the wells and cells were 
incubated for 30 minutes in a humid chamber at room temperature protected from the 
light. After being washed with PBS, cells were stained with primary rabbit anti-mouse 
Abs, anti-EEA1 (1:100) and anti-calnexin (1:200), for early endosomes and ER 
labeling, respectively, for 2 h, in a humid chamber at room temperature and protected 
from light. Then, primary Abs solutions were removed, cells washed with PBS and 
stained with secondary goat anti-rabbit IgG Alexa Fluor 488
®
 antibody (1:400), under 
the same conditions of primary Abs labeling. Confocal microscopy samples were 
prepared by depositing the coverslips (cell deposits face down) on clean fluorescence 
microscopy slides, using an excess of mounting media (Mowiol
® 
4-88) between the 
coverslip and the slide. Preparations were allowed to dry protected from light, for 30 
minutes, at 4º C and conserved under the same conditions until observation. For 
confocal microscopy imaging analysis, images were obtained by confocal microscopy 
(Leica DMI 4000 B Microscope-Leica TCS SPE; Leica source CTR 4000) and 
processed using the WCIF ImageJ Software. Images were processed using the 
colocalization plug-in of this software, for colocalization analysis. Raw images from 
each channel were used, the background was automatically subtracted and thresholds 
for both channels (red and green) were calculated. Pearson’s correlation coefficient (Rr) 
and Mander’s coefficients (M1 and M2) were calculated after running the colocalization 
finder. The colocalization percentages were calculated through the number of voxels for 
each channel with both, green and red channel intensities, above the threshold. 
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3.2.8. Statistical analysis  
All experimental results are expressed as mean ± standard deviation (SD). One-
way ANOVA and Turkey’s post test were performed to demonstrate statistical 
differences, using the SPSS software (version 21) for Windows
®
. Differences were 
considered statistically significant at p < 0.05. 
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4. Results 
 
4.1. Characterization of nanoparticles 
 
4.1.1. Ovalbumin entrapped-nanoparticles 
  
Biodegradable polymeric NPs derived from two different polymers, PLGA and 
PLGA-PEG, were prepared by double emulsion-solvent evaporation method and 
primarily optimized using OVA as a model antigen. 
Nanoparticles were physicochemical characterized for Z-Ave, PdI, ZP, η and 
surface morphology. Values of Z-Ave, PdI, ZP and η, measured in triplicate, are 
summarized in Table 2 and Table 3 according to the polymer, PLGA and PLGA-PEG, 
respectively. In each table, formulations were organized according to the internal 
aqueous phase (10 % (w/v) PVA or 8 % (w/v) PVA/0.1 % (wGCs/wpolymer) GCs) or to the 
external aqueous surfactants utilized (0.25 % (w/v) PVA or 0.125 % (w/v) PL), as well 
as to the entrapment or non-entrapment of OVA. 
 
Table 2 – Physicochemical properties of plain and ovalbumin (OVA)-entrapped PLGA 
nanoparticles, by size (Z-Ave), polydispersity index (PdI) and surface charge (ZP); evaluation 
of yield (η) (mean ± SD; N≥3; n=3). Statistical analysis: one-way ANOVA and Turkey’s post 
test. ZP, relative to plain formulations: * p < 0.05, ** p < 0.01 and *** p < 0.001.   
nd, not determined. 
 
 
 
FORMULATION DILUTION Z-Ave (nm) PdI ZP (mV) η (% (w/w)) 
PLGA_PVA_plain 
1:20 177±2 0.029±0.005 -2.01±0.12 
46.99±8.04x10-13 
1:200 177±2 0.131±0.032 -2.79±0.58 
PLGA_PVA_OVA 
1:20 179±2 0.046±0.009 -2.64±0.07** 
49.71±0.59 
1:200 176±3 0.114±0.064 -3.19±0.08 
PLGA_GCs_plain 
1:20 
170±4 0.093±0.027 -2.53±0.12 
77.12±3.61 
1:200 
171±3 0.095±0.016 -3.25±0.05 
PLGA_GCs_OVA 
1:20 
171±5 0.089±0.019 -2.48±0.53 
76.27±5.63 
1:200 
171±3 0.117±0.003 -3.22±0.64 
PLGA_PL_plain 
1:20 
217±30 0.298±0.093 -1.89±0.47 
nd 
1:200 
222±20 0.354±0.047 -2.99±0.32 
PLGA_PL_OVA 
1:20 
271±56 0.357±0.089 -2.88±0.29* 
nd 
1:200 
252±31 0.392±0.038 -3.27±0.48 
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Table 3 – Physicochemical properties of plain and ovalbumin (OVA)-entrapped PLGA-PEG 
nanoparticles, by size (Z-Ave), polydispersity index (PdI) and surface charge (ZP); evaluation 
of yield (η) (mean ± SD; N≥3; n=3). Statistical analysis: one-way ANOVA and Turkey’s post 
test. ZP, relative to plain formulations: * p < 0.05, ** p < 0.01 and *** p < 0.001.   
 
 
Except for PLGA_PL NPs whose formulation was not stable, all different PLGA 
and PLGA-PEG formulated NPs presented a size range between 170 and 187 nm, a PdI 
below 0.150, and a slightly negative surface charge, but still close to neutrality, with ZP 
values ranging from -1.22 to -3.27 mV.  In addition, the low SD obtained for the three 
parameters (Z-Ave, PdI and ZP), demonstrates that the double emulsion-solvent 
evaporation method used for NPs preparation is highly reproducible. Moreover, these 
parameters were shown to be independent on both internal (PVA or GCs) and external 
(PVA or PL) aqueous phase composition, since no statistically significant differences 
were detected between size and zeta potential (one-way ANOVA and Turkey’s post 
test) of NPs prepared with those different external or internal phases. Formulation 
stability was also maintained when OVA was entrapped into NPs, not being observed 
statistically significant differences between the size of antigen-loaded and plain NPs 
(one-way ANOVA and Turkey’s post test). In addition, dilutions of NP suspensions did 
not alter the carrier size and zeta potential. The yield obtained for formulations prepared 
with GCs in the internal phase was significantly higher (~ 75 % (w/w)) than those 
obtained for other formulations (~ 50 % (w/w)). 
Plain and OVA-loaded PLGA_PVA NPs were further characterized by AFM for 
their size, shape and surface morphology. Section analysis corroborates the results of 
FORMULATION DILUTION Z-Ave (nm) PdI ZP (mV) η (% (w/w)) 
PLGA-PEG_PVA_plain 
1:20 177±4 0.039±0.011 -2.02±0.15 
51.75±4.61 
1:200 181±5 0.138±0.021 -2.96±0.81 
PLGA-PEG_PVA_OVA 
1:20 179±3 0.031±0.012 -2.25±0.08 
51.41±5.99 
1:200 184±3 0.121±0.028 -2.74±0.78 
PLGA-PEG_GCs_plain 
1:20 178±6 0.084±0.032 -1.22±0.13 
72.52±2.70 
1:200 182±5 0.159±0.016 -1.63±0.18 
PLGA-PEG_GCs_OVA 
1:20 171±2 0.036±0.010 -2.38±0.09*** 
74.23±1.18 
1:200 174±3 0.109±0.018 -2.65±0.40 
PLGA-PEG_PL_plain 
1:20 186±1 0.034±0.011 -1.50±0.25 
53.12±3.06 
1:200 187±2 0.100±0.028 -2.10±0.55 
PLGA-PEG_PL_OVA 
1:20 184±2 0.021±0.002 -1.98±0.39 
54.82±2.95 
1:200 187±4 0.088±0.010 -2.16±0.18 
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DLS, presenting a homogeneous size distribution with a mean diameter close to 170 nm 
(Figure 3C). In addition, AFM images showed NPs with spherical shape, as can be seen 
in topography and 3D images (Figure 3A and 3B-left; and 3C). However, surface 
morphology analysis (phase images) of plain NPs is considerably different from the 
OVA-loaded ones. A smoother surface was examined for plain NPs (Figure 3A-right) 
comparing to OVA-entrapped NPs. The slight roughness observed for OVA-loaded NPs 
(Figure 3B-right) may suggest that the amount of protein entrapped into these carriers is 
not totally incorporated into the polymeric matrix, being a small portion adsorbed onto 
NP surface. 
 
 
 
 
1 x 1 µm2 ; Z = 433.3 nm 1 x 1 µm2 ; Z = 98.4 º
A.
1 x 1 µm2 ; Z = 433.3 nm 1 x 1 µm2 ; Z = 143.9 º
B.
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Figure 3 – Analysis of size, shape and surface morphology of nanoparticles (NPs) by Atomic 
Force Microscopy. Topography (left) and phase (right) images of (A) PLGA_PVA_plain NPs 
and (B) PLGA_PVA_OVA NPs. Section analysis and 3D image of (C) PLGA_PVA_plain NPs. 
 
The EE (% (w/w)) and LC (μg/mg) of model antigen determined by MicroBCATM 
protein assay and HPLC, are presented on Table 4, for the three different compositions 
of PLGA and PLGA-PEG NPs. Results were obtained indirectly through the 
quantification of OVA amount present in each of the three supernatants collected during 
the washing and centrifugation steps of NPs.  
EE was calculated as the percentage of antigen mass in the NPs over the initial 
amount of loaded antigen, while LC was determined as mass of associated agent per 
mass of polymer. 
 EE (% (w/w)) and LC (µg/mg) analysis from both methods suggest that 
significantly higher values were obtained for all NPs when determined by HPLC, 
achieving an EE between 84 % (w/w) and 93 % (w/w), and LC close to 22 μg/mg. In 
fact MicroBCA
TM
 determination evidenced EE ranging from 41 % (w/w) to 64 % (w/w) 
and LC values between 10 and 16 μg/mg. 
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Table 4 – Entrapment efficiency (EE, % (w/w)) and loading capacity (LC, µg/mg) of the 
ovalbumin (OVA) entrapped in PLGA and PLGA-PEG nanoparticles, determined by 
MicroBCA
TM
 protein assay and High Performance Liquid Chromatography (HPLC) (mean ± 
SD; N≥3; n=3). Statistical analysis: one-way ANOVA and Turkey’s post test. Relative to PVA 
and PL formulations: * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
 
 
nd, not determined. 
 
No statistically significant differences were seen between NPs prepared with 
PEGylated and non-PEGylated polymers for EE (% (w/w)) and LC (µg/mg) determined 
by both MicroBCA
TM
 and HPLC. Even though the different internal phase emulsion 
polymers used during NP preparation seem to have a pronounced impact on the 
entrapment of antigens (p < 0.05; one-way ANOVA and Turkey’s post test). In fact, 
results appear to be independent of the type of polymer (PLGA or PLGA-PEG), as well 
as, the nature of the surfactant present in the external aqueous phase (PVA or PL), since 
similar EE (% (w/w)) and LC (µg/mg) were observed (Table 4). However, EE (% 
(w/w)) and LC (µg/mg) seem to be dependent on the internal aqueous phase used, PVA 
or GCs, when determined by MicroBCA
TM
. NPs containing GCs have shown values of 
EE and LC close to 63 % (w/w) and 16 μg/mg, respectively, while PVA stabilized NPs 
presented EE between 42 % (w/w) and 53 % (w/w) and LC ranging from 10 μg/mg to 
13 μg/mg. Curiously, results obtained using HPLC method show that the PLGA-
PEG_GCs NPs present lower EE (% (w/w)) and LC (µg/mg) values than those prepared 
with PVA. In fact, the use of GCs in internal phase led to EE and LC values of 84 % 
(w/w) and 21 μg/mg, respectively, compared with those obtained for NP presenting only 
PVA in the internal phase (EE of 91-92 % (w/w) and LC of 23 μg/mg).               
 HPLC analysis also showed that the excess of PVA is efficiently removed from 
the surface of NPs during the washing and centrifugation procedure (data not shown). 
 
 
FORMULATION 
EE (% (w/w)) 
MicroBCATM ǀ HPLC 
LC (µg/mg) 
MicroBCATM ǀ HPLC 
PLGA_PVA_ OVA 42.56±5.92 ǀ 84.33±0.127 10.64±1.48 ǀ 21.08±0.03 
PLGA-PEG_PVA_OVA 53.43±5.73 ǀ 92.49±2.82 13.36±1.43 ǀ 23.12±0.70 
PLGA_GCs_OVA 64.01±2.90* ǀ 85.69±3.24 16.00±0.73* ǀ 21.42±0.81 
PLGA-PEG_GCs_OVA 62.82±3.88* ǀ 84.37±1.11* 15.71±0.97* ǀ 21.09±0.28* 
PLGA_PL_OVA 41.60±3.96 ǀ nd 10. 40±0.99 ǀ nd 
PLGA-PEG_PL_OVA 44.39±5.16 ǀ 91.16±2.93 11.10±1.63 ǀ 22.79±0.73 
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4.1.2. HIV-1 peptides entrapped-nanoparticles 
 
Taking into account the previous results (Z-Ave, PdI, ZP, η, EE and LC) obtained 
for model antigen OVA and the advantages of PEG in NP biodistribution, HIV-1 
peptides, T20 and T1249, were entrapped into biodegradable PLGA-PEG NPs using the 
same methodology. Results for Z-Ave, PdI and ZP are summarized in Table 5, in which 
formulations were also ordered according to the i) internal aqueous phase used (10 % 
(w/v) PVA or 8 % (w/v) PVA/0.1 % (wGCs/wpolymer) GCs); ii) stabilizers present at the 
outer water phase, 0.25 % (w/v) PVA or 0.125 % (w/v) PL, and the iii) entrapment/co-
entrapment of HIV-1 peptides. Since the evaluated parameters (size and ZP) have been 
shown to be independent of dilution factor for NPs obtained during the optimization 
procedure, the physicochemical characteristics of HIV-1 peptide-loaded NPs were 
determined using only the lower dilution factor (1:20).    
 
Table 5 – Physicochemical properties of plain or HIV-1 peptides (T20 and T1249)-entrapped 
PLGA-PEG nanoparticles, by size (Z-Ave), polydispersity index (PdI) and surface charge (ZP); 
(mean ± SD; N≥3; n=3). Statistical analysis: one-way ANOVA and Turkey’s post test. Relative 
to PLGA-PEG_plain for each formulation type: * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
In general, the different PEGylated PLGA NPs presented a mean hydrodynamic 
diameter (Z-ave) close to 170 nm (mean size range of 163 to 178 nm), a PdI below 0.1 
and a surface charge close to neutrality, with ZP values ranging from -1.17 to -2.36 mV. 
The double emulsion-solvent evaporation method proved to be extremely 
reproducible, observing the low SD values obtained for Z-Ave, PdI and ZP. It can also 
FORMULATION Z-Ave (nm) PdI ZP (mV) 
PLGA-PEG_PVA_plain  171±1 0.042±0.003 -1.72±0.15 
PLGA-PEG_PVA_T20  170±2 0.064±0.016 -2.39±0.62 
PLGA-PEG_PVA_T1249  163±1* 0.049±0.017 -2.15±0.29 
PLGA-PEG_PVA_T20_T1249  168±3 0.078±0.011 -1.56±0.48 
PLGA-PEG_GCs_plain  178±1 0.073±0.017 -1.33±0.29 
PLGA-PEG_GCs_T20  171±3* 0.053±0.018 -2.36±0.30 
PLGA-PEG_GCs_T1249  165±2** 0.060±0.018 -2.44±0.58* 
PLGA-PEG_GCs_T20_T1249  174±2 0.062±0.012 -1.61±0.15 
PLGA-PEG_PL_plain  175±3 0.036±0.019 -1.95±0.21 
PLGA-PEG_PL_T20  169±3* 0.048±0.017 -1.93±0.26 
PLGA-PEG_PL_T1249  164±2** 0.049±0.014 -1.31±0.31 
PLGA-PEG_PL_T20_T1249  172±1 0.095±0.013 -1.17±0.36* 
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be seen that the stability of PLGA-PEG NPs was not affected by the different HIV-1 
antigens entrapped, as well as by the nature of the polymers/surfactants used in the 
external or internal aqueous phases. In fact, the differences observed in Z-Ave, PdI and 
ZP values obtained for HIV peptide-loaded PLGA-PEG NPs were not statistically 
significant, despite the different entrapped antigens and the polymers used in the 
external or internal phases (one-way ANOVA and Turkey’s post test).  
On the other hand, statistical differences were found between size and zeta 
potential obtained for HIV-1 antigen-loaded NPs and those presented by plain or OVA-
loaded NPs (p < 0.05; one-way ANOVA and Turkey’s post test). 
A preliminary study was conducted to infer the stability  and degradation profiles 
of NPs. Accordingly, freshly prepared HIV-1 antigen-loaded PLGA-PEG NPs were 
stored at 4ºC for one month and Z-Ave, PdI and ZP parameters were measured after this 
period (Table 6).  
 
Table 6 – Physicochemical properties of HIV-1 peptide-loaded PLGA-PEG nanoparticles, by 
size (Z-Ave), polydispersity index (PdI) and surface charge (ZP), one month after preparation 
(mean ± SD; N≥3; n=3). 
    
From tables 5 and 6, it is evident that the physicochemical properties of HIV-1 
peptide-loaded PLGA-PEG NPs remained unaltered over the one month period. HIV-1 
peptide-loaded PLGA-PEG NPs did not show any tendency to aggregate, presented a 
mean hydrodynamic diameter close to 174 nm and a PdI below 0.1. Although the 
surface charge remained close to neutrality, a slight decrease in ZP was observed, which 
is consistent with polymer degradation and consequent exposure of carboxylic acid end-
groups.     
FORMULATION Z-Ave (nm) PdI ZP (mV) 
PLGA-PEG_PVA_T20  176±1 0.073±0.008 -3.90±1.08 
PLGA-PEG_PVA_T1249  166±5 0.076±0.015 -2.46±0.36 
PLGA-PEG_PVA_T20_T1249  172±0 0.070±0.028 -2.75±0.35 
PLGA-PEG_GCs_T20  179±3 0.109±0.018 -3.77±0.53 
PLGA-PEG_GCs_T1249  167±1 0.066±0.009 -2.08±0.93 
PLGA-PEG_GCs_T20_T1249  185±6 0.121±0.001 -2.69±0.66 
PLGA-PEG_PL_T20  175±0 0.074±0.018 -3.58±0.54 
PLGA-PEG_PL_T1249  170±3 0.078±0.012 -2.15±0.43 
PLGA-PEG_PL_T20_T1249  176±2 0.094 ± 0.009 -3.27±1.20 
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The EE (% (w/w)) and LC (μg/mg) of HIV-1 antigen-loaded NPs (Table 7) were 
also indirectly quantified by intrinsic fluorescence assay of aminoacids present in T20 
and T1249 peptides, using the supernatants collected during the three washing and 
centrifugation steps of PLGA-PEG NPs. 
Table 7 – Entrapment efficiency (EE, % (w/w)) and loading capacity (LC, µg/mg) of the HIV-1 
peptides (T20 and T1249) entrapped-PLGA-PEG nanoparticles, determined by intrinsic 
fluorescence assay (mean ± SD; N≥3; n=3). Statistical analysis: one-way ANOVA and Turkey’s 
post test. Relative to PLGA-PEG_PL_T20_T1249 formulation (between peptides): * p < 0.05, 
** p < 0.01 and *** p < 0.001. Relative to PLGA-PEG_PL for each peptide formulation 
(between external phases): 
#
 p < 0.05, ## p < 0.01 and ### p < 0.001. Relative to PLGA-
PEG_GCs for each peptide formulation (between internal phases): º p < 0.05, ºº p < 0.01 and ººº 
p < 0.001.  
 
Overall, NPs were able to co-entrap different HIV-1 antigens, presenting EE and 
LC values above 78 % (w/w) and 15 μg/mg, respectively. These values were similar to 
those obtained for carriers entrapping each antigen individually. On the other hand, the 
entrapment of those antigens appear to be dependent on the nature of the surfactant 
present in the external aqueous phase, showing higher EE and LC for formulations 
prepared using PVA. Internal aqueous phase composition also influenced EE and LC, 
where higher values were obtained for formulations developed using GCs. In addition, 
the highest EE and LC close to 93 % (w/w) and 19 μg/mg, were obtained when both 
HIV-1 antigens, T20 and T1249 peptides, were co-entrapped into PLGA-PEG_GCs 
NPs. 
The EE (% (w/w)) and LC (μg/mg) of PLGA-PEG NPs entrapping each HIV 
peptide individually were significantly affected by the composition of the external or 
FORMULATION 
EE (% (w/w)) 
Fluorescence 
LC (µg/mg) 
Fluorescence 
PLGA-PEG_PVA_T20 80.36±15.72
# 16.07±3.14# 
PLGA-PEG_PVA_T1249 78.22±8.84
# 15.64±1.77# 
PLGA-PEG_PVA_T20_T1249 86.30±1.53ºº 17.26±0.31ºº 
PLGA-PEG_GCs_T20 88.80±3.76
# 17.76±0.75# 
PLGA-PEG_GCs_T1249 82.49±6.80
## 16.50±1.36## 
PLGA-PEG_GCs_T20_T1249 92.65±1.78
## 18.53±0.36## 
PLGA-PEG_PL_T20 66.66±2.67*º 13.33±0.53*º 
PLGA-PEG_PL_T1249 48.39±9.84**
;ºº 9.68±1.97**;ºº 
PLGA-PEG_PL_T20_T1249 85.35±0.36ºº 17.07±0.07ºº 
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internal phases (p < 0.05). On the other hand, no differences were observed for EE (% 
(w/w)) and LC (μg/mg) presented by NPs entrapping different HIV-1 antigens, except 
for PLGA-PEG_PL (p < 0.05; one-way ANOVA and Turkey’s post test).  
 
4.2. Cell viability assay 
 
An AlamarBlue
® 
assay was performed to determine the effect of plain PLGA-
PEG NPs on the viability of murine immature BMDCs. Cells were incubated with 
crescent concentrations of the three different PLGA-PEG-based NPs (PLGA-
PEG_PVA, PLGA-PEG_GCs and PLGA-PEG_PL) (0.125, 0.25, 0.5 and 1 mg/mL) for 
24, 48 and 72 h. Triton X-100 was used as positive control. Cell viability (%) was 
normalized using PBS as negative control (100 %). 
As it can be seen in Figure 4, no cytotoxic effect was observed on BMDCs, over a 
wide range of concentrations of the three groups of PLGA-PEG NPs, at 24, 48 and 72 h 
post incubation. 
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Figure 4 – Cell viability (%) determined by AlamarBlue® assay with increasing concentrations 
(0.125-1 mg/mL) of three different groups of PLGA-PEG nanoparticles (PLGA-PEG_PVA, 
PLGA-PEG_GCs and PLGA-PEG_PL) on murine immature bone marrow dendritic cells (JAW 
SII, ATCC
®
CRL-11904
TM
), after 24, 48 and 72 hours of incubation (mean ± SD; N=3; n=6). 
Statistics: one-way ANOVA and Tukey’s post test. Relative to negative control (PBS): * p < 
0.05, ** p < 0.01 and *** p < 0.001. Between different concentrations for each formulation: # p 
< 0.05, ## p < 0.01 and ### p < 0.001. 
 
Indeed, cell viability remained close to 100 % and thus similar to the negative 
control PBS, even after 72 h of incubation with the three groups of PLGA-PEG NPs in 
concentrations ranging from 0.125 mg/mL to 1 mg/mL. Cell viability was thus 
independent of external and internal aqueous phase composition, NP concentration and 
incubation time. Moreover, the levels of cell viability obtained after 48 h and 72 h of 
incubation with nanoparticulate formulations were not statistically different from the 
negative control (PBS). Contrary, a mean viability of 20 % was observed for positive 
control (cells treated with 0.05 % (v/v) Triton X-100), which was significantly different 
(p < 0.001; one-way ANOVA and Turkey’s post test) than the one presented by cells 
after incubation with whichever nanoparticulate system under study and PBS. In 
addition, no statistically significant differences were seen between the cell viability 
obtained for the different concentrations tested for different types of formulations, with 
the exception of the one quantified after 24 h of incubation with 0.5 mg/mL of PLGA-
PEG_PVA NPs (p < 0.05; one-way ANOVA and Turkey’s post test). 
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4.3. Evaluation of peptide integrity 
 
Having in consideration the higher EE and LC values obtained for PLGA-PEG 
formulation containing GCs, as well as the absence of cytotoxic effect on BMDCs, this 
formulation was selected to assess the effect of formulation procedure on HIV-1 peptide 
structural integrity. The integrity of T20 and T1249 individually or co-entrapped into 
PLGA-PEG_GCs NPs was evaluated by PAGE, using SDS as denaturing agent (16 % 
resolving gel) (Figure 5). 
 
Figure 5 – Evaluation of the integrity of HIV-1 peptides, T20 and T1249, entrapped in PLGA-
PEG_GCs nanoparticles (NPs) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(16 % resolving gel). (1) Standard molecular weight markers (10-250 kDa); (2) and (3) positive 
controls: T1249 and T20 solutions (0.75 mg/mL), respectively; (4) PLGA-PEG_GCs_T1249 
NPs; (5) PLGA-PEG_GCs_T20 NPs; (6) PLGA-PEG_GCs_T20_T1249 NPs; and (7) negative 
control: PLGA-PEG_GCs_plain NPs. 
 
 It is possible see that all HIV-1 peptide-loaded NPs (loaded in wells 4, 5 and 6) 
have a similar pattern of migration and present a single band below the lower limit of 
the Mw marker (10 kDa), correspondent to HIV-1 peptides (T20 and T1249), which 
have molecular weights close to 5 kDa. In fact, the structure of the HIV-1 antigens 
entrapped into PLGA-PEG_GCs NPs seem not to be affected by the formulation 
procedure due to the presence of an unique band at a molecular weight similar to the 
one observed for positive controls, T20 and T1249 solutions (0.75 mg/mL), loaded in 
wells 2 and 3; as well as the absence of additional bands suggestive of peptide 
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fragmentation. Moreover, the previous results are corroborated by the non-existence of 
this band in plain NPs used as negative control (loaded in well 7). 
 
4.4. Uptake and intracellular trafficking of nanoparticles 
In order to verify the uptake of PLGA-PEG NPs by DCs, their intracellular 
trafficking and consequent ability to process and present antigens complexed with MHC 
class I and/or II molecules, confocal microscopy imaging studies were performed. 
BMDCs were incubated with fluorescent PLGA-PEG_GCs_plain NPs prepared using 
Rho-grafted PLGA (NPs-Rho), which presented physicochemical properties similar to 
non fluorescent PLGA_PEG_GCs_plain NPs. Thereafter, anti-EEA1 and anti-calnexin 
antibodies were added to BMDCs to visualize early endosomes and ER, respectively. 
Representative images of BMDCs obtained after 1, 5 and 20 h of incubation 
with NPs-Rho (red) and staining of subcellular organelles (green), as well as the 
colocalized pixels (in white) arised from the red-green merged images, are shown on 
Figure 6A. Qualitatively, it was possible to infer that a small number of NPs were taken 
up by BMDCs after 1 h of incubation, being a considerable amount of NPs adsorbed 
onto cell membranes (EEA1, 1 h). However, the intracellular internalization of NPs by 
BMDCs increased after 5 h of incubation (EEA1 and Calnexin, 5 h), confirming the 
further uptake of those NPs previously adsorbed onto cell membranes. After 20 h of 
incubation, the amount of NPs taken up by cells seem to be lower (EEA1 and Calnexin, 
20 h) than the one observed 5 h after of incubation, being still higher than those 
observed inside the cells after 1 h of incubation. Moreover, it was observed that the 
number of early endosomes increased with time (EEA1, 5 and 20 h). Regarding the 
intracellular localization, internalized NPs were localized in the perinuclear space as 
well as in the cytosol. Slightly orange regions resulting from the overlay of red and 
green channels indicate the colocalization of NPs-Rho (red) within acidic organelles 
(green), like early endosomes.                     
Quantitative analysis was also performed. The percentage of colocalization of 
NPs-Rho with each organelle is represented on Figure 6B (left). After 1 h, NPs-Rho 
presented 19.7±15.4 % and 34.7±25.3 % of colocalization with EEA1 and calnexin, 
respectively. After 5 h, the colocalization of NPs-Rho with organelles increased to 
59.7±7.8 % and 65.6±2.1 % for EEA1 and calnexin, respectively. Finally, after 20 h, the 
colocalization percentage of NPs-Rho with EEA1 and calnexin decreased to 56.3±5.3 % 
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and 53.7±19.1 %, respectively. The obtained results suggest that after 1 h of incubation, 
NPs achieved the endo-lysosomal pathway, being possible to observe NPs colocalized 
with organelles. During the following 4 h, colocalization levels were increased for both 
organelles, being then lower at 20 h. According to the colocalization percentage of the 
organelles with NPs-Rho, which ranged from 12.4±4.5 % to 66.9±2.1 %, saturation of 
organelles with NPs did not take place (Figure 6B, right). On Figure 6C (left), M1 
coefficient was found to be in accordance with the colocalization percentage of the red 
and green channels. The behavior of M2 coefficient is similar to M1, suggesting the 
dependence of the staining of NPs and organelles (Figure 6C, right). High correlation 
levels between NPs and organelle stains were observed through Rr values, which 
remained higher than 0.5, at all time points (Figure 6D).  
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Figure 6 – Uptake and intracellular trafficking of nanoparticles (NPs) by murine immature bone 
marrow dendritic cells (BMDCs), and colocalization analysis. (A) Confocal microscopy images 
of rhodamine-labeled NPs (Red) incubated with BMDCs for 1, 5 and 20 h. Early endosomes 
and endoplasmic reticulum were stained with rabbit anti-mouse anti-EEA1 and anti-calnexin, 
respectively, and then labeled with goat anti-rabbit IgG Alexa Fluor 488
®
 (green). Scale bars = 
20 µm. WCIF ImageJ software was used to obtain the colocalized pixels in white, from red and 
green channels (on right of the respective image), as well as, to quantify the percentage of 
colocalization of NPs (red pixels) with each organelle-staining antibody (green pixels) and vice 
versa (B, left and right, respectively), the Mander’s coefficient of red (M1) and green (M2) 
channels (C, left and right, respectively) and the Pearson’s correlation coefficient, Rr (D). Mean 
± SD from at least 40 cells from three independent images is represented.            
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5. Discussion 
 
New preventive and/or therapeutic strategies against HIV-1 infection are urgently 
needed to avoid the continuous increase in the AIDS incidence rates observed around 
the world (192). The goal essentially comprises the control and eradication of HIV-1 
infection through the development of an effective, safe and inexpensive vaccine with 
prophylactic/therapeutic properties, where both cellular and humoral immune responses 
are required. In fact, not only antibody and CD4
+
 Th lymphocyte-mediated immune 
responses are crucial, but also the induction of both virus-specific neutralizing 
antibodies, at the site of viral entry, and CD8
+
 Tc lymphocyte with cytotoxic effect 
seem to be crucial to impair the dissemination of this virus (193). Different vaccine 
strategies have been employed. Live attenuated or whole inactivated traditional vaccines 
were described as unsafe, causing unwanted side effects.  More recent vaccines 
composed by part of the pathogen, such as recombinant/synthetic proteins or peptides, 
or DNA enconding for these proteins, have been described as safe approaches, but also 
as poorly immunogenic, requiring the use of adjuvants to induce potent immune 
responses (194). Polymeric NPs have been widely investigated as a promising strategy 
for HIV vaccine delivery systems, acting as adjuvant by enhancing the antigen uptake 
by APCs that will elicit effective humoral and cellular immune responses, and 
protecting antigens from unfavorable in vivo environment after administration (195, 
196). 
This project aimed to develop biodegradable and biocompatible PLGA 
nanoparticulate systems as vaccine candidates to deliver entrapped HIV-1 gp41 
antigenic peptides to target highly specialized APCs, as DCs, in order to ultimately 
elicit an effective humoral and cellular immune responses, essentially with the 
production of neutralizing antibodies. It included the production and characterization of 
these antigen-loaded NPs, as well as the evaluation of their uptake and intracellular 
trafficking by target cells. 
 
5.1. Composition of nanoparticles 
  
The physicochemical properties of the selected materials and the formulation 
procedure used to prepare polymeric NPs play an important role in their physiochemical 
characteristics as well as in their in vitro and in vivo behavior. PLGA-based NPs have 
been widely used to carry antiretroviral drugs and for siRNA vaginal delivery aiming 
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HIV prophylaxis (178, 197, 198). PLGA is an FDA and European Medicine Agency 
(EMA) approved biocompatible and biodegradable polymer acceptable for different 
applications, including drug delivery. This polymer presents a residual cytotoxicity due 
to its metabolization via Krebs cycle after chemical hydrolysis into PLA and 
poly(glycolic acid) (PGA) monomers (199). PLGA NPs have the ability to interact and 
destabilize vesicular membranes that successfully result in the escape from 
endolysosomal route and in the delivery of entrapped cargo into cytoplasm (200, 201). 
The surface modification of PLGA NPs with PEG chains has also been reported to 
increase their intravaginal retention and reach an augment delivery of cargo, being 
useful for long-term prophylaxis (202). PEG is a hydrophilic, non-toxic and flexible 
molecule approved by the FDA for human use (203). The “PEGylation” process 
consists in coating NP surface with a hydrophilic layer and has been used not only to 
stabilize the formulation but especially to avoid the recognition of hydrophobic 
polymers by cells in the reticuloendothelial system (RES) as foreign, increasing their 
circulation half-life in bloodstream. In fact, this recognition process resultant from 
binding of opsonins is presented as one of the biggest barriers to the controlled delivery 
by NPs. Moreover, the linkage of specific ligands to the NP surface via PEG-grafted 
polymers has been applied for the targeting specific organs or subcellular organelles 
(204). PEG-grafted NPs were also reported to decrease the interaction of these carriers 
with digestive enzymes after oral administration (205). Different polymers have been 
used in the formulation of particulate vaccine delivery systems for HIV prophylaxis, 
such as PMMA (98), PG (99) and PLA (101). The potential use of PLGA was 
demonstrated by Zhu et al. (2012) who developed Eudragit microparticles encapsulated 
with HIV antigen-loaded PLGA NPs for oral administration (100). In addition, adjuvant 
properties of different polymeric NPs have been demonstrated by successful eliciting 
systemic and mucosal immune responses, as reviewed by Aline et al. (2009) and Caputo 
et al. (2009) (98, 206). Taking advantage of the unusual development of HIV vaccine 
delivery nanocarriers based on PLGA polymer and its higher biodegradation rate and 
lower hydrophobicity in vivo than other polymers such as PLA, PLGA and PLGA-PEG 
polymers were explored a NPs’ matrix in this study. 
Several methods such as solvent evaporation, salting-out, dialysis and 
supercritical fluid technology can be used to prepare polymeric NPs and their choice 
depends on several aspects, namely the type of polymeric system, route of 
administration, nature of active molecules and size distribution (207). PLGA NPs are 
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commonly prepared by emulsification-solvent evaporation technique, where two main 
strategies are used for those formulations: w/o single emulsion for hydrophobic drug 
encapsulation and w/o/w double emulsion to encapsulate hydrophilic entities, such as 
peptides, proteins and nucleic acids. In both cases, this technique consists in adding an 
aqueous phase, containing the stabilizer or surfactant, to an oil phase, composed by the 
polymer previously dissolved in an organic solvent (e.g., DCM). The formation of 
nanosized droplets is achieved by supplying energy to the system through high-speed 
homogenization or ultrasonication methods. In the specific case of a w/o/w emulsion, 
the first w/o emulsion is then added to a large volume of an external aqueous phase, 
containing a specific surfactant which will allow the formation of NPs. Thereafter, the 
active molecule-loaded solid nanospheres formed during solvent evaporation under 
continuous magnetic stirring at room temperature, or reduced pressure, can be collected 
by ultracentrifugation and washed to remove the excess of surfactants. Lately, NPs can 
be lyophilized (208). In this study, polymeric NPs were formulated using a modified 
w/o/w solvent evaporation method, originally described by Ogawa et al. (1988) (209). 
The various biomaterials used as internal or external aqueous phases were chosen 
in order to compare their influence in the physicochemical properties of NPs, such as 
size, surface charge, stability, EE (% (w/w)) and LC (µg/mL), as well as their 
cytotoxicity in vitro. Therefore, PLGA or PLGA-PEG-based NPs were produced by 
utilizing PVA as the internal and external stabilizing agent. PVA is a nonionic water-
soluble polymeric surfactant with excellent emulsifying properties (ampiphilic 
character), commonly used to stabilize the formulation of PLGA NPs and reduce 
emulsion surface tension (210). Lemoine and Préat (1998) observed that NPs’ size 
decreased when PVA was used in the internal aqueous phase. On the contrary, a 
residual influence was seen when this polymer was used in the external aqueous phase 
(211). However, some studies have shown adverse effects in animals, such as 
hypertension, organ lesions, anemia and depression of the central nervous system, from 
PVA subcutaneous and intravenous administration (212). Furthermore, there are still 
some concerns about PVA carcinogenicity (213). Consequently, residual PVA should 
be always removed by repetitive washing and centrifugation procedures. Moreover, PL 
was also used as an alternative surfactant to PVA, in the external aqueous phase. PL is a 
non-ionic triblock copolymer surfactant, also commonly used for PLGA-based NP 
formulation, which presents low toxicity and immunogenicity (214). Menon et al. 
(2011) prepared PLGA NPs coated with different pluronic surfactants, observing that 
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Pluronic F127 was the most biocompatible, which support this alternative choice (215). 
Chitosan is a highly biocompatible and biodegradable polysaccharide obtained from 
chitin deacetylation, found in exoskeleton of shellfish. This cationic polymer is usually 
studied as gene delivery system, due to its ability to complex with negatively charged 
DNA (216). Cs-containing microparticles have been shown to elicit protective immune 
responses, after IN immunization (217). Moreover, Beletti et al. (2012) demonstrated 
that the addition of Cs in the inner phase of the primary emulsion increased the EE of 
tenofovir loaded into PLGA NPs (218). According to this evidence, GCs was also used 
in the internal aqueous phase, in combination with PVA, in order to attain a higher EE 
and LC of antigens.          
In this study, PLGA and PLGA-PEG NPs formulation procedure was firstly 
optimized using OVA, as a model antigen. OVA is an albumin protein from chicken 
egg white of 45 kDa that has been widely studied as a model antigen (219, 220). After 
NP characterization and optimization, OVA was replaced by HIV-1 antigens, T20 and 
T1249 peptides. T20 or enfuvirtide is the only FDA approved HIV-1 fusion inhibitor 
since 2003 composed by 36 amino acids engineered directly from HIV-1 gp41 CHR 
sequence. It has the following amino acid sequence: CH3CO-Tyr-Thr-Ser-Leu-Ile-His-
Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-
Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 and a molecular weight of 4492 
Da (160, 221). T1249 is another strong inhibitor of HIV-1 composed by 39-mer peptide 
derived from CHR consensus sequences. It amino acid sequence is: CH3CO-Trp-Gln-
Glu-Trp-Glu-Gln-Lys-Ile-_-_-_-_-_-_-_-Thr-Ala-Leu-Leu-Glu-Gln-Ala-Gln-Ile-Gln-
Gln-Glu-Lys-Asn-Glu-Tyr-Glu-Leu-Gln-Lys-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Glu-
Trp-Phe-NH2 and presents a molecular weight around 5000 Da (160). 
Note that formulations of all nanoparticulate carriers were performed in triplicate 
in order to attain reliable statistical correlations. 
 
5.2. Physicochemical characterization of nanoparticles 
 
The goal of vaccination aims the induction of an appropriate immune response to 
confer protection against pathogen. Moreover, the delivery of antigens to APCs, 
especially DCs that are highly specialized to take up and process antigens, is crucial for 
the induction of T cell responses and the development of a protective immune response 
(105). In addition, the efficiency of antigen uptake into DCs has been shown to be 
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higher when encapsulated in NPs. However, it has been shown that the physicochemical 
properties of nanocarriers, such as size, surface charge and surface morphology, play an 
important role in the interaction between particles and APCs (222). 
The size is an important factor that affects the cellular uptake of particulate 
antigen carriers. However, the ideal size for NPs uptake by APCs remains an utopian 
issue, several studies indicate that these cells are able capture and process any antigen 
with similar dimensions of viruses (20-100 nm), bacteria or even cells (micrometer 
range) (104). Size of soluble or particulate material also influences the mechanism of 
entry and consequently the subsequent endocytic pathway. Commonly, virus particles 
range from 20 to 200 nm can be taken up via clathrin-dependent endocytosis (size < 200 
nm) (223) or via caveolae-mediated endocytosis (size range 50-100 nm) (224). 
Moreover, to elicit an effective and long-lasting immune response, antigen-loaded NPs 
should also migrate through the lymphatic system, being size an important determinant. 
While particles larger than 200-500 nm require to be transported by DCs, taking 24 
hours to achieved the lymphoid organs, NPs smaller than 200 nm travel directly through 
lymph drainage reaching the lymphoid organs within hours after administration, besides 
being also transported by DCs (225). PLGA NPs demonstrated higher uptake levels 
than microparticles (226). Moreover, effective cellular immune responses have been 
elicited by NPs encapsulating HIV-1 antigens and presenting an average mean diameter 
close to 200 nm (97, 206). 
Cellular uptake is also influenced by shape or surface morphology of these 
nanodelivery systems. According this fact, spherical gold NPs have been more 
efficiently taken up than rod-shaped NPs (227). In addition, PLGA elliptical particles 
took a longer period of time to be endocytosed by endothelial cells than spherical 
particles (228). Therefore, the latter constitutes a promising shape to be considered for 
vaccine delivery development.     
Finally, surface charge presents an important role on internalization ability, and 
shows to be dependent on the chemical nature of polymer and stabilizing agent, as well 
as on pH of dispersant. Apparently, as a result of ionic interactions established between 
positively charged particles and negatively charged cell membranes, cationic NPs 
present a higher extent of internalization than negatively or neutrally charged ones (229, 
230). In addition, it is believed that the internalization of anionic NPs occurs through 
the non-specific binding and aggregation of particles on cellular cationic sites, followed 
by endocytosis. Moreover, in order to increase the circulation time of these 
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nanocarriers, neutral charge may prevent unwanted interactions with cells (226). The 
surface charge of anionic delivery systems can be simply shifted to neutral by surface 
coating with PEG copolymer (231). Additionally, cationic NPs can also escape from 
lysosomal compartment after the internalization process, exhibiting perinuclear 
localization, whereas anionic or neutral particles are preferentially accumulated at 
lysosomes (232). However, NPs positively or negatively charged adsorb proteins 
present in the biological medium at higher extent than neutral carriers (233). Moreover, 
as reported by Albanese et al. (2012), the binding of charged NPs to a lipid bilayer can 
induce alterations, local gelation (anionic particles) or fluidity (cationic particles) in cell 
membranes, being responsible for some toxicity and adjustments on normal cell 
metabolism (234).  
Considering the main strategy of the present study to deliver HIV-1 antigenic 
peptides encapsulated into biodegradable and biocompatible nanocarriers that will target 
in vivo the professional antigen-presenting cells, namely DCs, polymeric NPs 
presenting ideal properties related to size, surface charge and morphology were 
successfully produced by a modified double emulsion-solvent evaporation method (190) 
using both polymers PLGA and PLGA-PEG. A model antigen was entrapped in those 
NPs to characterize NP physicochemical properties and optimize formulation procedure.  
Actually, with the exception of PLGA_PL unstable formulation, all formulated 
NPs analyzed by DLS and LDE, presented a mean hydrodynamic diameter less than 
200 nm, ranging between 170 and 187 nm, as well as a slightly negative surface charge, 
close to neutrality, with zeta potential values ranging from -1.22 to -3.27 mV (Table 2 
and 3). Moreover, the monodispersity of this nanoparticulate population was proved by 
lower PdI values, which were smaller than 0.15. In addition, it was also proved the high 
reproducibility of NP formulation method, observing the low SD obtained. The stability 
inherent to this nano-emulsion that ultimately lead to solid NPs, is principally evidenced 
by the absence of the flocculation phenomenon, naturally prevented by the steric 
stabilization of the sub-micrometric droplet size (235). AFM analysis for PLGA_PVA 
formulation (Figure 3) revealed a homogeneous population of NPs with spherical shape 
and a mean size close to 170 m, corroborating DLS results. Surface morphology was 
shown to be smooth for plain NPs. On the other hand, OVA-loaded NPs presented a 
slight roughness surface, which is thought to be due to the presence of antigen adsorbed 
onto NP surface that is supported by the modest amount of non-entrapped OVA 
detected in the supernatants. Adsorbed molecules onto NP surface have been shown to 
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be responsible for the non-desired burst release effect of antigens from NPs, 
corresponding to the initially increased release rate. This phenomenon was reported for 
PLGA-based NPs and is caused by the high hydrophobicity of this polymer associated 
with highly hydrophilic entrapped molecules, being closely related to the lost of 
efficacy when cargo attains the target site (236). Regarding antigen entrapment, NPs 
were prepared in the absence of antigen (plain NPs), to be used as control for antigen-
loaded nanocarrier composed by the different biomaterials under evaluation. The 
formulation process was shown to be antigen-independent, maintaining the stability of 
NPs when OVA was previously dissolved in the internal aqueous phase, since no 
statistically significant differences were observed (p > 0.05) between Z-Ave values 
obtained for OVA-loaded and plain NPs. As previously mentioned, different surfactants 
and polymers were tested as stabilizers in internal and external phases. The IP was 
modified by the addition of a water soluble Cs (GCs) to promote antigen entrapment. In 
addition, two different surfactants, 0.25 % (w/v) PVA and 0.125 % (w/v) PL solutions, 
were tested as EP in order to achieve the best stability and physicochemical 
characteristics suitable for antigen delivery. Previously optimized in our lab, PL and 
PVA concentrations had to be modified in order to obtain a highly stable formulation, 
inferred namely through their particulate size distribution and surface charge. The 
concentration of both polymers happened to be very different which was expected due 
to their distinct molecular weight, nature and consequent distinct physicochemical 
characteristics. Results obtained did not shown statistically significant differences (p > 
0.05) between the different biopolymers used for particle formulation. This fact 
supports previous findings (215), by indicating that the stability of nanoparticulate 
formulations seems not to be affected by the chemical structure/composition of either 
internal or external phases. The yield percentage was however significantly higher (~ 75 
% (w/w)) for formulations prepared with GCs at the internal phase than the others 
stabilized by both surfactants (~ 50 % (w/w)). 
After the physicochemical characterization of the nanoparticulate systems 
formulated in this research project, it is possible to postulate that the developed 
modified double emulsion method was highly reproducible and that the resultant 
particles constitute promising antigens delivery systems. As a result and according to 
the previously mentioned advantages of PEGylation in vivo, PLGA-PEG polymer was 
selected to proceed with the experimental work and thus to entrap HIV-1 peptides, T20 
and T1249. It is important to highlight that, to the best of our knowledge, this is the first 
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time that these HIV-1 peptides have been associated to a particulate delivery system. 
These NPs have been prepared following the same formulation method and testing the 
biomaterials previously used for OVA-loaded PLGA-PEG NPs. Moreover, HIV-1 
peptides were entrapped individually or co-entrapped into NPs to evaluate a potential 
synergistic effect between both immunogens, due to their delivery to a single immune 
cell. As expected, all HIV-1 antigen-loaded PLGA-PEG NPs presented a mean 
hydrodynamic diameter close to 170 nm (ranging from 163-178 nm), a surface charge 
close to neutrality (ranging from -1.17 to -2.36 mV) and a PdI below 0.1 (Table 5). 
Although statistical differences were observed between size and zeta potential (p < 
0.05) of HIV-1 antigen-loaded NPs and plain or OVA-loaded nanocarriers, HIV 
peptide-loaded NPs proved to be stable and not affected by the type of HIV-1 antigen 
entrapped or the nature of both internal and external aqueous phases (p > 0.05). 
Moreover, preliminary stability studies showed that formulations entrapping HIV-1 
antigens remained physicochemically unaltered for one month (Table 6), but additional 
studies should be performed following International Conference Guidelines (ICH) 
stability testing guidelines Q1A (237). Even though, the low SD values obtained for size 
biodistribution and surface charge (Z-Ave, PdI and ZP) of developed HIV-1 peptide-
loaded nanocarriers indicate that their production method is highly reproducible. In 
addition, their physicochemical properties evidence their potential extensive uptake by 
DCs, entrapped antigen delivery, as well as ability to be transported through the 
lymphatic system, reaching the lymph nodes, where a high number of DCs are found, 
after peripheral injection. 
 
5.3. Antigen loading analysis 
 
 The administration of proteins or peptides alone has presented real pitfalls as 
their limited oral bioavailability, due to epithelial barriers of the gastrointestinal tract, 
their gastrointestinal degradation by digestive enzymes, their short half-life in vivo and 
their non-diffusion across some biological barriers. Moreover, their rapid degradation 
and elimination supports the need for repeated injections through invasive routes, such 
as subcutaneous, to attain effective levels (238). To overcome these concerns, the 
encapsulation of proteins and peptides in NPs has arisen as a promising tool, 
contributing with additional benefits such as the protection of proteins against 
enzymatic and hydrolytic degradation in vivo, the maintenance of their integrity and 
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activity, the improvement of their bioavailability and the target of specific organs, cell 
or even subcellular organelles for cargo delivery. Moreover, antigens can be loaded into 
NPs by two different methods: (1) the incorporation of antigen into NPs, during the 
production method and (2) the adsorption of antigen onto NP surface, after their 
formulation. Studies for delivery of vaccines for HIV using polymeric NPs have relied 
in both methods (99, 239). As explained before, in the experimental work under 
discussion, the antigens OVA (model antigen) and HIV-1 peptides were entrapped into 
polymeric NPs during the formulation process. The loading analysis was performed 
indirectly by determining the EE, (% (w/w)) and LC (μg/mg) of NPs through the 
quantification of the amount of antigen that remained dissolved in the supernatants 
collected during the three washing and centrifugation steps. Indeed, ultracentrifugation 
is classified as the most appropriate way to separate NPs from non entrapped antigens. 
High EE (percentage of loaded amount of entrapped antigen relative to the total amount 
used in NP formulation) and LC (loaded amount of entrapped antigen per total amount 
of polymer) are need to allow low number of administrations but also to obtain 
nanoparticulate suspensions presenting low viscosity, which is important to have in 
consideration specially when the vaccine is intended to be administered through a 
parenteral route. However, unlike high EE, the poor loading of drugs (around 1 %, 
meaning that NPs are carrying 1 mg of active molecule per 100 mg polymer) have been 
reported for PLGA-based NPs (236).  
For model antigen, OVA, EE and LC were determined by MicroBCA
TM
 protein 
assay and HPLC method. MicroBCA
TM
 protein assay is based on the determination of 
total protein concentration which is revealed by a proportional color change from green 
to purple and measured at 560 nm using a colorimetric technique, according to 
manufacturer instructions. Indeed, the MicroBCA
TM
 assay is based on the detection of 
Cu
+
 by bicinchoninic acid (BCA), after the reduction of Cu
2+
 by protein in alkaline 
conditions (240). The quantification of the protein present in supernatants is attained by 
the use of a standard calibration curve prepared using the same protein used in NP 
formulation. The HPLC method has been widely reported for the isolation and 
quantification of proteins or peptides of interest (241) and was applied in this study 
using a size-exclusion column for OVA isolation. The presence of this protein in 
supernatants was detected at 220 nm by spectrophotometric analysis, after 8-9 min of 
run. The supernatants of plain NPs were used as controls. Significantly higher EE and 
LC values were obtained using both methods, for all PLGA and PLGA-PEG NPs (Table 
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4). However, HPLC method reached the highest results (EE: 84-93 % (w/w); LC: 21-23 
μg/mg) against the MicroBCATM determination (EE: 41-64 % (w/w); LC: 10-16 
μg/mg). The loading parameters appear to be independent of the presence of PEG 
polymer in PLGA polymeric chains, since no statistically significant differences were 
seen (p > 0.05) for EE (% (w/w)) and LC (μg/mg) obtained for PLGA-PEG and PLGA 
NPs correspondent NPs. Likewise, the surfactant present in the external aqueous phase, 
PVA or PL, did not affect antigen entrapment by PEGylated and non-PEGylated NPs. 
Unlike, higher values of EE (~ 63 % (w/w)) and LC (~ 16 μg/mg) were observed for 
formulations that used GCs in internal aqueous phase in comparison with formulations 
stabilized by PVA surfactant (PVA and PL formulations), which presented an EE in the 
range of 42-53 % (w/w) and LC ranging from 10 to 13 μg/mg, analyzed by 
MicroBCA
TM
. Thus, EE (% (w/w)) and LC (μg/mg) were shown to be dependent on the 
internal aqueous phase composition, having statistical significance (p < 0.05). These 
results also suggested that Cs interfere with the antigen entrapment in PLGA and 
PLGA-PEG NPs, increasing the capacity of NPs to entrap higher amounts of antigen. 
Curiously, the loading analysis for PLGA-PEG_GCs obtained using HPLC method has 
also shown to be dependent on the internal phase, but in reverse order. Formulations 
developed using only PVA as an internal aqueous phase stabilizer presented higher 
values for EE (91-92 % (w/w)) and LC (23 μg/mg) than the correspondent formulation 
that also contained GCs in this primary emulsion phase (EE: 84 % (w/w); LC: 21 
μg/mg). Besides being less expensive and a rapid process, not requiring higher sample 
or mobile phase volumes, MicroBCA
TM
 protein assay is less sensitive than HPLC 
method. Moreover, MicroBCA
TM 
solution can interfere with several substances, as 
chelating agents and strong acids or bases, which are commonly present in the 
supernatants obtained from NP formulation process (242). 
The EE (% (w/w)) and LC (μg/mg) were also indirectly quantified for HIV-1 
antigens entrapped into PLGA-PEG NPs, by intrinsic fluorescence assay of aminoacid 
residues present into peptides T20 and T1249 structures. Fluorescence is described as 
the photon emission by molecules, after being transiently stimulated to a higher 
excitation state, with radiant energy from an outside source. The release of the adsorbed 
energy as a fluorescent photon happen during the process of energy collapse, where the 
excited electron return to its initial ground state, almost immediately after its excitation 
(243). The molecules able to fluorescing are called fluorophores, being proteins and 
peptides included. Into proteins and peptides, tryptophan, tyrosine and phenylalanine 
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residues are accepted as intrinsic fluorophores that can emit fluorescence. Specifically, 
tryptophan, tyrosine and phenylalanine residues present a maximum wavelength (λmax) 
of absorption/excitation at 280, 274 and 257 nm and emission at 348, 303 and 282 nm, 
respectively. However, tryptophan and tyrosine can be simultaneously excited at 280 
nm. In addition, tryptophan is an excellent probe to distinguish native and unfolded 
proteins because it is very sensitive to the polarity of surrounded environment (244). 
In general, higher EE (~ 78 % (w/w)) and LC (~ 15 μg/mg) values were observed 
for the entrapment or co-entrapment of HIV-1 peptides into PLGA-PEG NPs (Table 7). 
However, the loading parameters were shown to be dependent on the internal and 
external aqueous phases composition. When PVA was used as external phase stabilizer, 
instead of PL, in formulation process, higher EE (% (w/w)) and LC (μg/mg) were 
obtained, presenting values that varied between 78-93 % (w/w) for EE and 16-19 μg/mg 
for LC. Unlike, when GCs is included in the internal phase, NPs were able to entrap 
higher amounts of antigens (EE: 83-93 % (w/w); LC: 17-19 μg/mg) than those prepared 
using only PVA (EE: 48-86 % (w/w); LC: 10-17 μg/mg). Indeed, statistically significant 
differences have been observed for EE (% (w/w)) and LC (μg/mg), when different NPs 
stabilized by distinct external or internal phases are compared with each other for each 
entrapped HIV-1 antigen (p < 0.05). Moreover, the best results accomplished for 
loading parameters were obtained with the co-entrapment of T20 and T1249 peptides 
into PLGA-PEG_GCs NPs (EE: 93 % (w/w) and LC: 19 μg/mg). It is still important to 
refer that all results were obtained in triplicate from three isolated assays. Giving 
credibility to previous results, Wang et al. (2008) reported a LC of γ-PGA NPs (~ 200 
nm) entrapping the recombinant HIV-1 p24 of 25 µg/mg, which was determined by the 
Lowry method (245). In addition, Himeno et al. (2010) also quantified the amount of 
encapsulated recombinant HIV-1 gp120 into γ-hPG (γ-PG-graft-Phe) NPs (200 nm) as 
10 µg per mg NP, by the previous reported method (99). 
5.4. Cytotoxic effect of nanoparticles 
 
Long-term in vitro cytotoxicity experiments were designed to determine whether 
any of the components used for the production of PLGA-PEG NPs compromised the 
viability of murine immature BMDCs. Indeed, BMDCs were incubated with crescent 
concentrations (0.125-1 mg/mL) of PLGA-PEG_plain NPs (PLGA-PEG_PVA, PLGA-
PEG_GCs and PLGA-PEG_PL), and their viability was quantified by AlamarBlue
® 
assay after 24, 48 and 72 h of incubation. This bioassay allows inferring about the 
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cytotoxicity of substances within several chemical classes, measuring quantitatively the 
cellular proliferation based on the detection of mitochondrial dehyrogenase metabolic 
activity. In response to chemical reduction of growth medium resulting from cell 
growth, the fluorescent/colorimetric redox indicator incorporated into AlamarBlue
® 
reagent changes its color from oxidized (non-fluorescent, blue) to reduced (fluorescent, 
pink) form. AlamarBlue
® 
assay presents several advantages against MTT (thiazolyl blue 
tetrazolium bromide) assay such as i) its solubility in water, not requiring extraction 
steps; ii) stability allowing the continuous cell growth monitoring; iii) non-toxicity to 
cells, not interfering with normal metabolism and not compromising technician health. 
Moreover, AlamarBlue
® 
reagent can be reduced by FMNH2, FADHs, NADH, NADPH 
(higher reducing power) and cytochromes (lower reducing power) unlike the MTT 
reagent which cannot be reduced by the latter (246). 
Quantification of cellular proliferation was performed by spectrophotometric 
analysis, monitoring absorbance at 570 nm (reduced/pink) and 600 nm (oxidized/blue). 
Triton X-100 and PBS were used as positive and negative controls, respectively. Cell 
viability (%) was normalized for negative control, PBS (100 %). All PLGA-PEG_plain 
formulations did not show long-term toxicity to BMBCs over the 72 hours time period 
(Figure 4). Moreover, cell viability was close to 100 %, analogous to the negative 
control PBS, for the lowest (0.125 mg/mL) to the highest (1 mg/mL) NP concentration, 
after 72 h of incubation. The AlamarBlue
® 
assay did not shown any statistically 
significant  effect (p > 0.05) on cell viability between the distinct formulation 
components used in external (PVA or PL) and internal (PVA or GCs) aqueous phases, 
for all tested concentrations and incubation periods, comparing to negative control 
(PBS). On the other hand, and as expected, a decrease on cell viability of 20 % was 
observed for cells treated with 0.05 % (v/v) Triton X-100, employed as positive control, 
being observed statistically significant differences (p < 0.001; one-way ANOVA and 
Turkey’s post test) in the values obtained for all tested formulations and cell incubated 
with negative control.  
These results support the fact that no toxic residues from the organic solvent 
(DCM) used in the formulation process remains in NPs, being completely evaporated 
after 1 hour of evaporation phase. The AlamarBlue
® 
assay also confirmed that the 
different components used in internal or external aqueous phases during the formulation 
development allow the preparation of stable and non-toxic NPs. Moreover, these results 
also suggest that PVA has been completely washed through washing and centrifugation 
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steps, not reducing thus the safety of NPs. The results confirmed the statement that 
PLGA-PEG is biocompatible. However, the PEGylation of polymer might have also 
contributed to the absence of cytotoxicity due to its higher hydrophilicity and non-
toxicity, also promoting NP biocompatibility (203). 
According to the previous results obtained for PLGA-PEG formulation using GCs 
on internal aqueous phase, such as high EE (% (w/w)) and LC (µg/mg) and non-toxic 
effect, these specific NPs were used in the following studies. 
 
5.5. Peptide integrity evaluation 
 
The maintenance of integrity and antigenicity of proteins and peptides entrapped 
into NPs represents an essential feature on their bioavailability and ability to induce 
effective immune responses. Particularly, the encapsulation of proteins into PLGA 
particles or other polymeric release systems by the emulsion solvent evaporation 
method has presented some negative aspects. Instability problems of entrapped proteins 
and peptides due to the contact with organic solvents and the use of high-shear devices 
remain a challenge (247). Indeed, the formation of a water/organic solvent interface in 
the first step of the double emulsion procedure has been recognized as a major 
destabilizing factor for proteins, resulting in their interfacial adsorption onto the 
hydrophobic polymer, followed by protein denaturation and aggregation. Moreover, the 
protein unfolding can be easily achieved via shear stress caused by temperature 
extremes, with the use of sonicators or homogenizers predominantly during the 
formation of the primary emulsion (248). Additionally, protein denaturation or 
aggregation may induce undesired side effects, such as immunogenicity or toxicity 
beyond its therapeutic inactivity (249). To solve these problems, research community 
has been focused in the optimization of the formulation process, in order to improve 
protein stability. The use of organic solvents less hydrophobic (250) and several 
stabilizer agents (251), the reduction of sonication time (252) as well as higher solvent 
evaporation rates (213) have been reported to reduce the risk of degradation of particle 
payload. 
The integrity of HIV-peptides, T20 and T1249, entrapped individually or co-
entrapped into PLGA-PEG_GCs NPs was evaluated by SDS-PAGE (16 % resolving 
gel). The PAGE method is used to separate proteins or peptides according to their 
charge, size and shape, in response to an electrical field via pores present in the gel 
matrix. Moreover, under denaturing conditions, protein sample is treated with SDS and 
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β-mercaptoethanol, attaining a primary structure charged negatively and the reduction 
of disulfide bonds formed by cysteines, respectively. Then, proteins will be separated 
electrophoretically moving through the polyacrylamide gel matrix toward the anode, 
according to their molecular weight (253, 254). In this assay, it was possible to see 
(Figure 5) that all antigens extracted from the different HIV-1 peptides-loaded NPs 
(PLGA-PEG_GCs_T1249, PLGA-PEG_GCs_T20 and PLGA PEG_GCs_T20_T1249) 
presented a similar pattern of migration, showing an unique band correspondent to HIV-
1 peptides, T20 and T1249 (Mw ~ 5 kDa), below the lower limit of the molecular 
weight marker (10 kDa). Moreover, these migration patterns were identical to those 
obtained for positive controls, T20 and T1249 standard solution (0.75 mg/mL), which is 
supposed to present a single band at the Mw ~ 5 kDa. These similar patterns of 
migration and the absence of additional bands, suggestive of peptide fragmentation, 
indicated that HIV-1 antigens entrapped into PLGA-PEG_GCs NPs are not structurally 
affected by the double emulsion procedure, remaining intact. In addition, these 
observations were corroborated by the absence of the same band in the negative control, 
composed by PLGA-PEG_GCs_plain NPs. 
According to the obtained results, it can be inferred that the formulation procedure 
used in NP preparation did not affect the structural integrity and the stability of HIV-1 
peptides, entrapped individually or co-entrapped. However, nothing about the 
antigenicity of peptides was possible to conclude. Western blotting techniques could be 
performed in the future to provide this information.                              
 
5.6. Uptake and intracellular trafficking of nanoparticles 
 
To verify if formulated NPs were internalized and to characterize their 
intracellular trafficking, BMDCs were incubated for 1, 5 and 20 h with fluorescent 
PLGA-PEG_GCs_plain NPs, due to the presence of Rho-grafted PLGA. Moreover, 
anti-EEA1 and anti-calnexin Abs were added to BMDCs to stain early endosomes 
(MHC class I and II pathways) and endoplasmic reticulum (MHC class I pathway), 
respectively that were further visualized by confocal microscopy. The study of the 
intracellular traffic of these polymeric delivery systems is only undoubtedly attained if 
fluorophores-grafted polymers are used for NP preparation. In fact, probes covalently 
linked to polymeric surface constitute a better option than the entrapment of soluble 
probes into NPs, due to probe leakage and the resulting misinterpretation. 
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DCs have demonstrated preference to taken up smaller particles, as viral size 
particles, whereas larger particles, as those within bacterial size range, are preferentially 
ingested by macrophages (144). The formulated Rho-NPs, presenting mean diameters 
lower than 200 nm, were taken up by BMDCs and higher internalization levels were 
observed with increasing incubation time (Figure 6). Furthermore, distinct intracellular 
pathways were observed for Rho-labeled NPs. Following NPs uptake by DCs, the 
entrapped antigens can be processed by different pathways. NPs can be hydrolyzed into 
endolysosomes, where proteins are processed by lysosomal proteases into peptides. 
These specific peptides are loaded onto MHC class II molecules to be presented on cell 
surface for recognition by CD4
+
 Th cells – a pathway involved in Th cell activation 
(255). In the meantime, some of the phagocytosed particles can follow the 
endolysosomal escape, being slowly hydrolyzed, releasing its cargo into the cytosol. 
Released proteins are degraded by the proteosomes into smaller peptides that will be 
subsequently translocated into the ER by the TAP. There, the complex formed by 
peptides loaded onto MHC class I molecules migrates to the cell surface to be recognize 
by CD8
+
 Tc cells (phagosome-to-cytosol cross presentation pathway) – a pathway 
involved in CTL activation (256). Results suggest that the uptake of NPs showed to 
increase with increasing incubation time, presenting high values of particle uptake after 
5 and 20 h of incubation. The slow attainment of endolysosomes, with most of NPs are 
colocalized around the cell membrane after 1 h of incubation, may be due to the 
PEGylated surface of NPs, providing delayed NP recognition and uptake by targeted 
cells (203, 257). This delay in the uptake may however provide effective immune 
responses due to a longer exposition of antigen. Moreover, the significant colocalization 
levels (50 to 60 %) with early endosome protein marker EEA1 support the hypothesis 
that this nanocarrier can travel mainly through endolysosomal vesicles pathway, 
inducing the antigen presentation on cell surface via MHC class II molecules to CD4
+
 
Th cells. In addition, the high colocalization levels (50 to 70 %) with the ER protein 
marker calnexin confirmed the suspicion that cross-presentation of antigens to CD8
+
 
cells via MHC class I molecules was also achieved. The concrete mechanism of 
endolysosomal escape is not clear, although two mechanisms are proposed for PLGA-
based NPs. The first mechanism is based on the pH change via acidification of PLGA 
NPs into endosomes, through the formation of hydrogen bonds between hydronium ions 
and carboxyl groups of lactic (pKa 3.1) and glycolic (pKa 3.8) acids, which leads to the 
alteration of PLGA surface charge, from negative in neutral pH to positive in acidic pH. 
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This phenomenon results in the local interaction between positively charged NPs and 
negatively charged endosomal membranes and allow the release of NPs into the 
cytoplasm (200). Otherwise, the osmotic pressure can be increased due to the influx of 
hydronium and chloride ions during endosomal acidification, leading to the rupture of 
the endosomal membrane and release of its content in the cytoplasm (258). 
Additionally, the decrease of colocalization levels of NPs with early endosomes from 5 
to 20 h after incubation can suggest the escape of NPs from these vesicles, their 
acumulation in the cytosol and the prolonged release of entrapped antigens over time, 
suggesting the potential use of these NPs as a single-dose vaccine.  
These observations propose that the developed HIV-1-loaded NPs are in fact 
promising vaccine delivery systems to present antigens by MHC class I and II 
pathways, promoting a complete and harmonized immune response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
6. Conclusions and Future Prospects 
 
The main goal of the present study is the development and characterization of a 
prophylactic vaccine for HIV-1, possibly also with immunotherapeutic application, 
using biodegradable and biocompatible polymeric NPs to deliver HIV-1 antigenic 
peptides. These studies will allow the selection of most promising delivery systems to in 
vivo target DCs, which are professional APCs of the immune system able to capture 
antigens and initiate coordinated innate and adaptative immune responses. 
During this year, PLGA and PLGA-PEG NPs were primarily prepared and 
optimized using the model antigen OVA. The physicochemical properties of these 
nanocarriers were further evaluated, namely through the assessment of their mean size 
distribution, surface charge and morphology, EE and LC. The composition of internal 
and external aqueous phases was varied by the addition different biopolymers as GCs 
and PVA or PL, in order to achieve the best antigen entrapment and formulation 
stability, respectively. Overall, except for the PLGA_PL unstable formulation, the 
results demonstrated that the nanocarriers presented ideal size and surface charge for 
cellular uptake, and high EE and LC, values. Moreover, NP stability was shown to be 
independent from the composition of both internal and external phases. Taking into 
account the high reproducibility obtained using the modified double emulsion method to 
prepare these promising antigens-loaded nanocarriers and the advantages of PEGylation 
in vivo, HIV-1 peptides (T20 and T1249) were further entrapped individually or in 
association  into PLGA-PEG NPs, using the same methodology and varying the internal 
and external aqueous phase, as reported above. The physicochemical characterization 
(Z-Ave, PdI and ZP) has shown that HIV-1 peptide-loaded nanocarriers are highly 
reproducible and present physicochemical properties adequate for an extensive uptake 
by DCs, promoting antigen recognition, processing and presentation. Moreover, the 
highest values for EE (% (w/w)) and LC (µg/mg) were obtained when PVA and GCs 
are used in external and internal phase, respectively. In addition, no toxic effect on 
targeted DCs was observed for all formulations tested for HIV-1 antigens entrapment, 
during 72 h of incubation.  
Considering all the referred results, the PLGA-PEG nanocarriers prepared using 
GCs and PVA on internal and external aqueous phase, respectively, were recognized as 
the most promising system, being thus selected for following studies. Fluorescent 
PLGA-PEG_GCs_plain NPs formulated with Rho-grafted PLGA were internalized by 
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DCs and have been shown to follow distinct intracellular pathways: i) endolysosomal 
pathway for the antigen presentation on cell surface via MHC class II molecules to 
CD4
+
 cells and ii) cross-presentation pathway via ER for the antigen presentation on 
cell surface to CD8
+
 cells via MHC class I molecules. Furthermore, the HIV-1 antigens 
entrapped or co-entrapped into PLGA-PEG_GCs NPs remained intact and stable, not 
being affected structurally by the formulation procedure. 
These observations suggest that the PLGA-PEG_GCs NPs constitute a promising 
platform for the delivery of HIV-1 antigens to DCs acting as vaccine delivery systems 
to promote an efficient immune response.     
In the future, different experiments are needed to confirm the potential of this 
formulation and therefore to achieve a long-awaited vaccine against HIV-1.   
 
6.1. Evaluation of peptide antigenicity by Imunoblotting 
   
In order to confirm the maintenance of the antigenicity or activity of entrapped 
HIV-1 peptides into PLGA-PEG_GCs NPs, a western blotting assay should be 
performed. Primarily, HIV-1 peptide samples will be separated by SDS-PAGE using the 
process described in Materials and Methods section for the evaluation of peptide 
integrity. In addition, peptides negatively charged will be transferred and immobilized 
on nitrocellulose membrane positively charged. The membrane will be incubated with 
primary antibody which will bind to the peptide, forming the complex antibody-peptide. 
Thereafter, a conjugated secondary antibody (antibody-enzyme) will be used to bind to 
primary antibody. Enzymes as alkaline phosphatase (AP) and peroxidase will function 
as a molecular signaling of complex primary antibody-peptide, allowing the 
visualization of detected peptide. An added chromogenic substrate will be degraded by 
secondary antibody-conjugated enzyme giving an insoluble precipitate colocalized with 
the primary antibody bounded to the peptide.   
 
6.2. Cellular uptake and intracellular trafficking studies of peptide-loaded NPs 
 
The cellular uptake of peptide-loaded NPs prepared by w/o/w method and the 
intracellular trafficking and fate of NPs and peptides separately inside murine immature 
BMDCs will be assessed by flow cytometry and confocal microscopy. For this purpose, 
NPs and HIV-1 antigens will be labeled with different fluorescent probes.    
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6.2.1. Flow cytometry analysis 
 
BMDCs will be seeded in plates and incubated overnight to allow cell attachment. 
After old medium removal, fluorescent PLGA_PEG_GCs NPs in fresh medium will be 
added in triplicates and incubated for 1, 5 and 20 h. Negative and positive controls will 
be composed by cells in medium, without NPs, and fluorescent NPs, respectively. 
Thereafter, medium will be removed, wells washed and cells harvested by trypsinization 
and centrifuged. Finally, cells will be resuspended in flow cytometry buffer and stored 
at 4 ºC until analysis. The percentage of fluorescent cells in the population will be 
measured using a flow cytometer. 
 
6.2.2. Confocal microscopy imaging analysis 
 
The procedure will be similar to that reported previously in the section Materials 
and Methods. BMDCs will be seeded on coverslips previously covered with PLL, and 
incubated overnight, allowing cell attachment. Without removing the medium, 
fluorescent PLGA-PEG_GCs NPs with entrapped fluorescent HIV-1 peptides will be 
added to cells and incubated for 1, 5 and 20 h. After incubation, cells will be washed, 
fixed and lastly permeabilized for antibody staining. Moreover, a blocking solution will 
also be used to prevent antibody unspecific binding. Cells will be stained with primary 
rabbit anti-mouse Abs, anti-EEA1 for early endosomes, anti-Rab7a for early and late 
endosomes, anti-LAMP1 for late endosomes and lysosomes and anti-calnexin for ER, 
being then labeled with secondary goat anti-rabbit antibody. Cell plasma membrane and 
nucleus will be also labeled. Finally, confocal microscopy preparations will be 
assembled and analyzed. The co-localization of fluorescent NPs or peptides with 
fluorescent organelles will evidence their intracellular location. 
 
6.3. Study of endocytic pathways involved in NPs internalization 
 
BMDCs will be seeded in plates for flow cytometry and confocal microscopy 
analysis. After cellular incubation with one of the following molecules: cytochalasin D, 
rottlerin, chlorpromazine, dynasore, genistein, nystatin and sucrose, NPs will be added 
for 1, 5 or 20 h at 37 °C. Analyses will be performed by confocal microscopy or flow 
cytometry as described. After treatment of BMDCs with the inhibitors, OVA Alexa 
Fluor® 647 will be used as control for clathrin-mediated endocytosis.  
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6.4. In vivo assay testing HIV-1 prophylactic effect 
 
Animals will be allowed to acclimate to the new environment for 1 week prior 
vaccination. Female 4-6 weeks old BALB/c mice (n = 5/group) will be subcutaneously 
(s.c.) immunized on day 1 and boosted twice at days 14 and 28, with 100 µL of 10 µg of 
T20 and/or T1249 dissolved in saline, entrapped or co-entrapped into PLGA-PEG_GCs 
nanospheres, or admixed with CpG adjuvant (10 µg). Tail vein blood samples will be 
collected at day 0 prior immunization and at days 7, 21, and 43 after immunization, and 
spleens isolated at the end of the experiment for immunological assays. Serum will be 
prepared from clotted blood and stored at -20 ºC until analysis (190). 
 
6.4.1. Serology 
 
The presence of antigen specific antibodies (IgG, IgG1 and IgG2a) in sera and at 
mucosal (IgA, IgG) vaginal and lung lavages will be searched by Enzyme Linked 
Immunosorbent Assay (ELISA) on mice samples tested individually. 
 
6.4.2. Cytokines assays 
 
Spleens will be removed at the end of the experiment and cell homogenisates be 
prepared. Supernatants will be used for the quantification of secreted Th1/Th2 cytokines 
(IL-2, IL-4, IL-5, IL-6, IL- 10, TNF-α and IFN-γ) using an ELISA kit. 
 
6.5. Antibody reactivity against HIV-1 peptides   
 
ELISA plates will be coated overnight with recombinant HIV-1 peptides, T20 and 
T1249. Plates will be washed with ELISA-washing buffer and blocking solution. Mice 
antiserum will be added to the microplates and incubated for 1 h at room temperature. 
After another wash, AP-conjugated goat anti-mouse IgG or IgA will be added as a 
secondary antibody, for 1h at 37 ºC. After a final washing step, a colorimetric reaction 
is developed with the addition of p-nitrophenylphosphate (pNPP) substrate and read at 
405 nm on a microplate reader. Negative and positive controls will be serum from pre-
immune mice and from HIV-1-infected individuals, respectively. In this case, the 
secondary antibody will be AP-conjugated anti-human IgG or IgA (193). 
 
 
72 
 
6.6. Neutralizing assay 
 
Primary virus isolates will be obtained from HIV-1-infected Portuguese patients. 
A single-round viral infectivity assay will be performed using a luciferase reporter gene 
assay to assess the neutralizing activity of mice serum against HIV-1 primary isolates. 
Cells will be added to culture plates overnight in complete growth medium, allowing 
their attachment before the addition of serum and virus dilutions. Thereafter, a mixing 
of heat-inactivated mice sera with virus will be incubated with cells for 1 h at 37°C. 
After culture medium removal from each well, cells will be lysed directly in the plate 
with One-Glow luciferase assay substrate reagent. Plates will be immediately analyzed 
for luciferase activity on a luminometer, using target cells and medium as controls. 
Virus neutralization titer is defined by the maximal dilution of plasma required to 
decrease virus production by 50 % two days after infection and is exhibited as the 
percent inhibition of viral infection (luciferase activity) at each serum dilution: % 
inhibition = [1 – (luciferase serum samples/luciferase without serum samples)] x 100 
(193). 
 
6.7. Lyophilization process optimization and NPs stability studies 
 
Lyophilization process will be optimized in order to evaluate the stability of those 
antigen-entrapped NPs. For this purpose, different lyoprotectants at different 
proportions and cycles of lyophilization should be tested. The optimization of this 
procedure will be guided by Differential Scanning Calorimetry, which is a thermal 
analyze methodology that will for example allow the prevention of collapse, 
consequence of high temperatures, through the previous determination of glass 
transition temperature and collapse temperature. Moreover, the stability of NPs with 
entrapped or co-entrapped HIV-1 antigens (T20 and T1249) should be assess for at least 
six months, measuring physicochemical parameters (Z-Ave, PdI and ZP) as well as their 
EE (% (w/w)) and LC (µg/mL), month after month (237).         
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